[go: up one dir, main page]

EP2173724B1 - Quinazolinone compounds and methods of use thereof - Google Patents

Quinazolinone compounds and methods of use thereof Download PDF

Info

Publication number
EP2173724B1
EP2173724B1 EP08771527A EP08771527A EP2173724B1 EP 2173724 B1 EP2173724 B1 EP 2173724B1 EP 08771527 A EP08771527 A EP 08771527A EP 08771527 A EP08771527 A EP 08771527A EP 2173724 B1 EP2173724 B1 EP 2173724B1
Authority
EP
European Patent Office
Prior art keywords
chloro
compound
oxo
phenylamino
dihydroquinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP08771527A
Other languages
German (de)
French (fr)
Other versions
EP2173724A2 (en
Inventor
Jifeng Liu
Syed M. Ali
Mark A. Ashwell
Ping Ye
Yousheng Guan
Shi-Chung Ng
Rocio Palma
Dan Yohannes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of EP2173724A2 publication Critical patent/EP2173724A2/en
Application granted granted Critical
Publication of EP2173724B1 publication Critical patent/EP2173724B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • Cancer is the second leading cause of death in the United States, exceeded only by cardiovascular disease.
  • Cancer Facts and Figures 2005, American Cancer Society, Inc. Despite recent advances in cancer diagnosis and treatment, surgery and radiotherapy may be curative if a cancer is found early, but current drug therapies for metastatic disease are by and large only palliative and seldom offer a long-term cure. Even with new chemotherapies entering the market, the need continues for effective new drugs used either in monotherapy or in combination with existing agents as first line therapy, and as second and third line therapies in treatment of resistant tumors.
  • One approach for cancer treatment is targeting mitotic processes of mammalian cells.
  • the therapeutic agents targeting mitosis include the taxanes, and the camptothecin class of topoisomerase I inhibitors.
  • Mitotic kinesins are enzymes essential for assembly and function of the mitotic spindle, but are not generally part of other microtubule structures, such as in nerve processes. Mitotic kinesins play an essential role during all phases of mitosis. These enzymes are "molecular motors" that transform energy released by hydrolysis of ATP into mechanical force which drives the directional movement of cellular cargoes along microtubules. The catalytic domain sufficient for this task is a compact structure of approximately 340 amino acids. During mitosis, kinesins organize microtubules into the bipolar structure that is the mitotic spindle.
  • Kinesins mediate movement of chromosomes along spindle microtubules, as well as structural changes in the mitotic spindle associated with specific phases of mitosis.
  • Experimental perturbation of mitotic kinesin function causes malformation or dysfunction of the mitotic spindle, frequently resulting in cell cycle arrest and cell death.
  • KSP also termed Eg5
  • KSP belongs to an evolutionarily conserved kinesin subfamily of plus-end-directed microtubule motors that assemble into bipolar homotetramers consisting of antiparallel homodimers.
  • KSP associates with microtubules of the mitotic spindle.
  • Microinjection of antibodies directed against KSP into human cells prevents spindle pole separation during prometaphase, giving rise to monopolar spindles and causing mitotic arrest and induction of programmed cell death.
  • KSP and related kinesins in non-human organisms bundle antiparallel microtubules and slide them relative to one another, thus forcing the two spindle poles apart.
  • KSP may also mediate anaphase B spindle elongation and focusing of microtubules at the spindle pole.
  • HsEg5 Human KSP (also termed HsEg5) has been described [ Blangy, et al., Cell, 83:1159-69 (1995 ); Whitehead, et al., Arthritis Rheum., 39:1635-42 (1996 ); Galgio et al., J. Cell Biol., 135:339-414 (1996 ); Blangy, et al., J. Biol. Chem., 272:19418-24 (1997 ); Blangy, et al., Cell Motil Cytoskeleton, 40:174-82 (1998 ); Whitehead and Rattner, J.
  • Quinazolinone derivatives are privileged structures present in many biologically active compounds such methaqualone, a sedative-hypnotic agent, chloroqualone, an antitussive agent, and piriqualone, an anticonvulsant. It has been known that quinazolinones and derivatives have a wide variety of biological properties such as hypnotic, analgesic, anticonvulsant, antitussive and anti-inflammatory activities.
  • Quinazolinone derivatives for which specific biological uses have been described include U.S. Patent No. 5,147875 describing 2-(substituted phenyl)-4-oxoquinazolines with bronchodilator activity is described.
  • U.S. Patent Nos. 3,723,432 , 3,740,442 , and 3,925,548 describe a class of 1-substituted-4-aryl-2(1H)-quinazolinone derivatives useful as anti-inflammatory agents.
  • European patent publication EP 0 056 637 B1 claims a class of 4(3H)-quinazolinone derivatives for treating hypertension.
  • European patent publication EP 0 884 319 A1 describes pharmaceutical compositions of quinazolin-4-one derivatives used for the treatment of neurodegenerative, psychotropic, and drug and alcohol induced central and peripheral nervous system disorders.
  • Quinazolinone derivatives are one of a growing list of therapeutic agents used for the treatment of cellular proliferate disorders, including cancer.
  • PCT WO 96/06616 describes a pharmaceutical composition containing a quinazolinone derivative to inhibit vascular smooth cell proliferation.
  • PCT WO 96/19224 uses this same quinazolinone derivative to inhibit mesangial cell proliferation.
  • U.S. Patent Nos. 4,981,856 , 5,081,124 , and 5,280,027 describes the use of quinazolinone derivatives to inhibit thymidylate synthase, the enzyme that catalyzes the methylation of deoxyuridine monophosphate to produce thymidine monophosphate which is required for DNA synthesis.
  • U.S. Patent Nos. 5,747,498 and 5,773,476 describes quinazolinone derivatives used for the treatment of cancer characterized by over-activity or inappropriate activity of tyrosine receptor kinase.
  • U.S. Patent No. 5,037,829 claims (1H-azol-1-ylmethyl) substituted quinazoline compositions for the treatment of carcinomas that occur in epithelial cells.
  • PCT WO 98/34613 describes a composition containing a quinazolinone derivative useful for attenuating neovascularization and for treating malignancies.
  • U.S. Patent 5,187,167 describes pharmaceutical compositions comprising quinazolin-4-one derivatives that possess antitumor activity.
  • the present invention provides a compound of formula I, or pharmaceutically acceptable salts thereof:
  • R1 is selected from the group consisting of H, alkyl, aryl, substituted aryl , haloaryl, biaryl, or bis-aryl, alkenyl, alkynyl, heteroaryl, cycloalkyl, heterocyclyl, haloalkyl, and perfluoroalkyl
  • X is selected from the group consisting of NR2, O, S and CHR2; R1 and R2, taken together, may form a ring
  • R2 is selected from the group consisting of hydrogen, alkyl including lower alkyl, aryl, alkenyl, alkynyl, heteroaryl, alkylheteroaryl, cycloalkyl, heterocyclyl, and perfluoroalkyl
  • R3 is selected from the group consisting of hydrogen, alkyl including lower alkyl, ary
  • Each Z is C.
  • Each R10 is independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, amino, cyano, alkoxy, alkylthio, methylenedioxy, or haloalkyloxy; alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylamino, dialkylamino, alkylsulfonyl, arylsulfonyl, alkylcarboxy, carboxyamino, carboxyamido, aminocarbonyl, and alkylsulfonamido; R11, R12, R13, R14, and R15 are independently selected from the group consisting of hydrogen, alkyl, aryl, alkylaryl, heteroaryl, oxaalkyl, oxaalkylaryl, and substituted oxaalkylaryl.
  • the stereochemistry of the compound is of "R" configuration.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula I in combination with a pharmaceutically acceptable carrier or excipient.
  • the pharmaceutical composition further comprises a second chemotherapeutic agent.
  • the present invention further provides compounds for use in a method of treating a cell proliferative disorder.
  • the method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, or a prodrug or metabolite thereof, in combination with a pharmaceutically acceptable carrier, wherein said cell proliferative disorder is treated.
  • the cell proliferative disorder is a precancerous condition.
  • the cell proliferative disorder is a cancer.
  • the cancer is adenocarcinoma, squamous carcinoma, sarcoma, lymphoma, multiple myeloma, or leukemia.
  • the cancer is lung cancer, colon cancer, breast cancer, pancreatic cancer, prostate cancer, acute leukemia, chronic leukemia, multiple melanoma, ovarian cancer, malignant glioma, leiomyosarcoma, hepatoma, or head and neck cancer.
  • the cancer can be primary cancer or metastatic cancer.
  • the compound of formula I, or a pharmaceutically acceptable salt thereof is administered in combination with a second chemotherapeutic agent.
  • the compounds of the present invention are inhibitors of mitotic kinesins, the mitotic kinesin KSP in particular.
  • the compounds of the present invention are useful for treating cellular proliferative diseases including cancer.
  • the present invention relates to new aryl quinazolinone derivatives, their pharmaceutically acceptable salts and stereoisomers that can be used to treat cellular proliferative diseases, disorders associated with KSP kinesin activity, and inhibit KSP kinesin.
  • aryl quinazolinone derivatives are compounds of formula I, or pharmaceutically acceptable salts thereof:
  • R1 is selected from the group consisting of H, alkyl, aryl, substituted aryl, haloaryl, bi aryl, or bis aryl, alkenyl, alkynyl, heteroaryl, cycloalkyl, heterocyclyl, haloalkyl, and perfluoroalkyl;
  • X is selected from the group consisting of NR2, O, S and CHR2; R1 and R2, taken together, may form a ring; when X is CHR2, R4 is alkynyl, or alkenyl;
  • R2 is selected from the group consisting of hydrogen, alkyl including lower alkyl, aryl, alkenyl, alkynyl, heteroaryl, alkylheteroaryl, cyclo
  • Each Z is independently selected from the group consisting of N, and C; m is 0 when Z is N.
  • Each R10 is independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, amino, cyano, alkoxy, alkylthio, methylenedioxy, or haloalkyloxy; alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylamino, dialkylamino, alkylsulfonyl, arylsulfonyl, alkylcarboxy, carboxyamino, carboxyamido, aminocarbonyl, and alkylsulfonamido;
  • R11, R12, R13, R14, and R15 are independently selected from the group consisting of hydrogen, alkyl, aryl, alkylaryl, heteroaryl, oxaalkyl, oxaalkylaryl, and substituted oxaalkylaryle.
  • A is 0, 1, or 2.
  • A is 1, and R5 and R6 are H.
  • m is 1.
  • n 3.
  • n is 2.
  • R8 and R9 are H.
  • X is NR2. In a further embodiment, X is NH 2 . In an alternative embodiment, X is O or S.
  • X is CHR2. In a further embodiment, X is ethynyl.
  • Y is a bond
  • R1 is phenyl
  • R2 is H.
  • R3 is H.
  • R4 is ethynyl
  • R5 and R6 are H.
  • Q is absent.
  • Q is CO, CH2, CHR12, or SO2.
  • R7 is unsubstituted or substituted phenyl.
  • W is H.
  • R8 and R9 are H.
  • alkyl includes saturated aliphatic groups, including straight-chain alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl), branched-chain alkyl groups (e.g., isopropyl, tert -butyl, isobutyl).
  • Alkyl further includes alkyl groups that have oxygen, nitrogen, or sulfur atoms replacing one or more hydrocarbon backbone carbon atoms.
  • a straight chain or branched alkyl has six or fewer carbon atoms in its backbone ( e . g ., C 1 -C 6 for straight chain, C 3 -C 6 for branched chain), and more preferably four or fewer.
  • alkyl also includes both "unsubstituted” and “substituted alkyls", the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbon of the hydrocarbon backbone.
  • substituents can include, for example, alkyl, alkenyl, alkynyl, hydroxyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxyacid, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, aryl
  • alkylaryl or aralkyl moiety is an alkyl moiety substituted with an aryl (e.g., methylphenyl (benzyl)).
  • aryl e.g., methylphenyl (benzyl)
  • Alkyl also includes the side chains of natural and unnatural amino acids.
  • Aryl includes groups with aromaticity, including 5- and 6-membered "unconjugated", or single-ring aromatic groups that may include from one to four heteroatoms, as well as “conjugated”, or multicyclic systems with at least one aromatic ring.
  • aryl groups include phenyl, pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like.
  • aryl includes multicyclic groups, e.g., tricyclic, bicyclic, e .
  • naphthalene benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, naphthidine, indole, benzofuran, purine, benzofuran, deazapurine, or indolizine.
  • aryl groups having heteroatoms in a ring structure may also be referred to as "aryl heterocycles", “heterocycles”, “heterocyclyls”, “heteroaryls” or “heteroaromatics” e.g ., pyridine, pyrazole, pyrimidine, furan, isoxazole, imidazole[2, l,b]thiazole, triazole, pyrazine, benzothiophene, imidazole, or thiophene.
  • aryl heterocycles e.g pyridine, pyrazole, pyrimidine, furan, isoxazole, imidazole[2, l,b]thiazole, triazole, pyrazine, benzothiophene, imidazole, or thiophene.
  • the aryl ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxyacid, alkylcarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, carboxyalkyl, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and
  • alkenyl includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double bond.
  • alkenyl includes straight-chain alkenyl groups (e.g ., ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl), branched-chain alkenyl groups, cycloalkenyl ( e.g ., alicyclic) groups ( e.g ., cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl groups, and cycloalkyl or cycloalkenyl substituted alkenyl groups.
  • alkenyl further includes alkenyl groups, which include oxygen, nitrogen, or sulfur replacing one or more hydrocarbon backbone carbons.
  • a straight chain or branched chain alkenyl group has six or fewer carbon atoms in its backbone (e.g .. C 2 -C 6 for straight chain, C 3 -C 6 for branched chain.)
  • cycloalkenyl groups may have from three to eight carbon atoms in their ring structure, and more preferably have five or six carbons in the ring structure.
  • C 2 -C 6 includes alkenyl groups containing two to six carbon atoms.
  • alkenyl also includes both “unsubstituted alkenyls” and “substituted alkenyls”, the latter of which refers to alkenyl moieties having substituents replacing a hydrogen on one or more hydrocarbon backbone carbon atoms.
  • substituents can include, for example, alkyl groups, alkenyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxyacid, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates,
  • Alkynyl includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond.
  • alkynyl includes straight chain alkynyl groups (e.g ., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl), branched chain alkynyl groups, and cycloalkyl or cycloalkenyl substituted alkynyl groups.
  • alkynyl further includes alkynyl groups having oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more hydrocarbon backbone carbons.
  • a straight chain or branched chain alkynyl group has six or fewer carbon atoms in its backbone (e.g .. C 2 -C 6 for straight chain, C 3 -C 6 for branched chain).
  • C 2 -C 6 includes alkynyl groups containing two to six carbon atoms.
  • alkynyl also includes both “unsubstituted alkynyls” and “substituted alkynyls”, the latter of which refers to alkynyl moieties having substituents replacing a hydrogen on one or more hydrocarbon backbone carbon atoms.
  • substituents can include, for example, alkyl groups, alkenyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxyacid, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates,
  • lower alkyl includes an alkyl group, as defined above, but having from one to ten, more preferably from one to six, carbon atoms in its backbone structure.
  • Lower alkenyl and “lower alkynyl” have chain lengths of, for example, 2-5 carbon atoms.
  • amine or “amino” includes compounds where a nitrogen atom is covalently bonded to at least one carbon or heteroatom.
  • Alkylamino includes groups of compounds wherein nitrogen is bound to at least one additional alkyl group. Examples of alkylamino groups include benzylamino, methylamino, ethylamino, and phenethylamino.
  • Dialkylamino includes groups wherein the nitrogen atom is bound to at least two additional alkyl groups. Examples of dialkylamino groups include dimethylamino and diethylamino.
  • Arylamino and “diarylamino” include groups wherein the nitrogen is bound to at least one or two aryl groups, respectively.
  • Alkylarylamino refers to an amino group which is bound to at least one alkyl group and at least one aryl group.
  • Alkaminoalkyl refers to an alkyl, alkenyl, or alkynyl group bound to a nitrogen atom which is also bound to an alkyl group.
  • amide or "aminocarboxy” includes compounds or moieties that contain a nitrogen atom that is bound to the carbon of a carbonyl or a thiocarbonyl group.
  • alkaminocarboxy groups that include alkyl, alkenyl, or alkynyl groups bound to an amino group bound to a carboxy group. It includes arylaminocarboxy groups that include aryl or heteroaryl moieties bound to an amino group that is bound to the carbon of a carbonyl or thiocarbonyl group.
  • alkylaminocarboxy include moieties wherein alkyl, alkenyl, alkynyl and aryl moieties, respectively, are bound to a nitrogen atom which is in turn bound to the carbon of a carbonyl group.
  • Amides can be substituted with substituents such as straight chain alkyl, branched alkyl, cycloalkyl, aryl, heteroaryl, or heterocycle. Substituents on amide groups may be further substituted.
  • Acyl includes compounds and moieties that contain the acyl radical (CH 3 CO-) or a carbonyl group.
  • Substituted acyl includes acyl groups where one or more of the hydrogen atoms are replaced by for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxyacid, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and
  • Acylamino includes moieties wherein an acyl moiety is bonded to an amino group.
  • the term includes alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido groups.
  • alkoxy or "alkoxyl” includes substituted and unsubstituted alkyl, alkenyl, and alkynyl groups covalently linked to an oxygen atom.
  • alkoxy groups or alkoxyl radicals
  • alkoxy groups include methoxy, ethoxy, isopropyloxy, propoxy, butoxy, and pentoxy groups.
  • substituted alkoxy groups include halogenated alkoxy groups.
  • the alkoxy groups can be substituted with groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxyacid, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkyls
  • cycloalkyl includes saturated acyclic groups (e.g., cyclopropyl, cyclopentyl, cyclohexyl, cyclohexyl, cycloheptyl, cyclooctyl).
  • Preferred cycloalkyls have from three to eight carbon atoms in their ring structure, and more preferably have five or six carbon atoms in the ring structure.
  • Cycloalkyls includes both "unsubstituted cycloalkyls" and “substituted cycloalkyls", the latter of which refers to replacing a hydrogen on one or more of the carbons in the ring structure.
  • substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxyacid, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkyls
  • heterocyclyl or “heterocyclic group” include closed ring structures, e.g ., 3-to 10-, or 4- to 7-membered rings, which include one or more heteroatoms.
  • Heteroatom includes atoms of any element other than carbon or hydrogen. Examples of heteroatoms include nitrogen, oxygen, or sulfur.
  • Heterocyclyl groups can be saturated or unsaturated and include pyrrolidine, pyrazine, pyrimidine, oxolane, 1,3-dioxolane, thiolane, tetrahydrofuran, tetrahydropyran, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams such as azetidinones and pyrrolidinones, sultams, and sultones.
  • Heterocyclic groups such as pyrrole and furan can have aromatic character. They include fused ring structures such as quinoline and isoquinoline. Other examples of heterocyclic groups include pyridine and purine.
  • the heterocyclic ring can be substituted at one or more positions with such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxyacid, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido,
  • Heterocyclic groups can also be substituted at one or more constituent atoms with, for example, a lower alkyl, a lower alkenyl, a lower alkoxy, a lower alkylthio, a lower alkylamino, a lower alkylcarboxyl, a nitro, a hydroxyl, -CF 3 , or -CN, or the like.
  • thioalkyl includes compounds or moieties which contain an alkyl group connected with a sulfur atom.
  • the thioalkyl groups can be substituted with groups such as alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxyacid, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, s
  • carbonyl or “carboxy” includes compounds and moieties which contain a carbon connected with a double bond to an oxygen atom.
  • moieties containing a carbonyl include, but are not limited to, aldehydes, ketones, carboxylic acids, amides, esters, anhydrides, etc.
  • thiocarbonyl or "thiocarboxy” includes compounds and moieties which contain a carbon connected with a double bond to a sulfur atom.
  • hydroxy or "hydroxyl” includes groups with an -OH or -O - .
  • halogen includes fluorine, bromine, chlorine, iodine, etc.
  • perhalogenated generally refers to a moiety wherein all hydrogens are replaced by halogen atoms.
  • C1-C6 includes one to six carbon atoms (C1, C2, C3, C4, C5 or C6).
  • C2-C6 includes two to six carbon atoms (C2, C3, C4, C5 or C6).
  • C3-C6 includes three to six carbon atoms (C3, C4, C5 or C6).
  • C3-C8 includes three to eight carbon atoms (C3, C4, C5, C6, C7 or C8).
  • C5-C8 includes five to eight carbon atoms (C5, C6, C7 or C8).
  • any heteroatom or carbon atom with unsatisfied valences is assumed to have the hydrogen atom to satisfy the valences.
  • the compounds described herein may have asymmetric centers.
  • substituted means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound.
  • 2 hydrogens on the atom are replaced.
  • Keto substituents are not present on aromatic moieties.
  • “Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • the present invention also provides methods for the synthesis of the compounds of Formula I.
  • the present invention provides a method for the synthesis of compounds according to the following schemes, and the protocols shown in the Examples.
  • compositions are described as having, including, or comprising specific components, it is contemplated that embodiments of the compositions may also consist essentially of, or consists of, the recited components.
  • methods or processes are described as having, including, or comprising specific process steps, the processes may also include embodiments that consist essentially of, or consist of, the recited processing steps.
  • steps or order for performing certain actions is immaterial so long as the invention remains operable.
  • two or more steps or actions can be conducted simultaneously.
  • the synthetic processes of the invention can tolerate a wide variety of functional groups, therefore various substituted starting materials can be used.
  • the processes generally provide the desired final compound at or near the end of the overall process, although it may be desirable in certain instances to further convert the compound to a pharmaceutically acceptable salt, ester, or prodrug thereof.
  • the compounds of this invention with general formula (I) may be prepared according to the following schemes from commercially available starting materials or starting materials, which can be prepared using literature procedures. These schemes show the preparation of representative compounds of this invention.
  • the compounds of formula I of this invention may be prepared by employing reaction as shown in schemes 1 and 2.
  • the present invention further provides a compound prepared by one of the synthetic processes disclosed herein, such as those disclosed in the Examples.
  • the present invention also provides compound for use in a method for the treatment of a cell proliferative disorder in a mammal comprising administering to a mammal in need of such treatment, a therapeutically effective amount of a compound of Formula 1.
  • the invention further provides the use of a compound of Formula I for the preparation of a medicament useful for the treatment of a cell proliferative disorder.
  • the invention provides for the treatment of cancer or precancerous conditions in a mammal comprising administering to a mammal in need of such treatment, a therapeutically effective amount of a compound of Formula I.
  • the mammal can be any mammal, e.g., a human, a primate, mouse, rat, dog, cat, cow, horse, pig.
  • the mammal is a human.
  • An effective amount of a compound of Formula I is used in a method to treat a cell proliferative disorder in a mammal without affecting normal cells of the mammal.
  • a therapeutically effective amount of a compound of Formula I is used in a method for treating cancer in a mammal by inducing cell death in cancer cells without affecting normal cells in the mammal. Cell death can occur by either apoptosis or necrosis mechanisms.
  • administration of a therapeutically effective amount of a compound of Formula I induces cell death in abnormally proliferating cells without inducing cell death in normal cells.
  • the invention also provides a method of protecting against a cell proliferative disorder in a mammal by administering a therapeutically effective amount of a compound of Formula I to a mammal.
  • the invention also provides the use of a compound of Formula I for the preparation of a medicament useful for the prevention of a cell proliferative disorder.
  • the invention provides for the prevention of cancer in a mammal comprising administering to a mammal in need of such treatment, a therapeutically effective amount of a compound of Formula I.
  • the compounds of the invention may be administered in the form of pharmaceutical compositions, e.g., as described herein.
  • a "subject" can be any mammal, e.g., a human, a primate, mouse, rat, dog, cat, cow, horse, pig, sheep, goat, camel. In a preferred aspect, the subject is a human.
  • a "subject in need thereof” is a subject having a cell proliferative disorder, or a subject having an increased risk of developing a cell proliferative disorder relative to the population at large (e.g., a patient that has been diagnosed with a genetic or environmental risk factor).
  • a subject in need thereof has a precancerous condition.
  • a subject in need thereof has cancer.
  • cell proliferative disorder refers to conditions in which the unregulated and/or abnormal growth of cells can lead to the development of an unwanted condition or disease, which can be cancerous or non-cancerous, for example a psoriatic condition.
  • psoriatic condition refers to disorders involving keratinocyte hyperproliferation, inflammatory cell infiltration, and cytokine alteration.
  • the cell proliferation disorder is cancer.
  • cancer includes solid tumors, such as lung, breast, colon, ovarian, prostate, malignant melanoma, non-melanoma skin cancers, as well as hematologic tumors and/or malignancies, such as childhood leukemia and lymphomas, multiple myeloma, Hodgkin's disease, lymphomas of lymphocytic and cutaneous origin, acute and chronic leukemia such as acute lymphoblastic, acute myelocytic or chronic myelocytic leukemia, plasma cell neoplasm, lymphoid neoplasm and cancers associated with AIDS.
  • proliferative diseases which may be treated using the compositions of the present invention are epidermic and dermoid cysts, lipomas, adenomas, capillary and cutaneous hemangiomas, lymphangiomas, nevi lesions, teratomas, nephromas, myofibromatosis, osteoplastic tumors, and other dysplastic masses and the like.
  • proliferative diseases include dysplasias and disorders of the like.
  • monotherapy refers to administration of a single active or therapeutic compound to a subject in need thereof.
  • monotherapy will involve administration of a therapeutically effective amount of an active compound.
  • Monotherapy may be contrasted with combination therapy, in which a combination of multiple active compounds is administered, preferably with each component of the combination present in a therapeutically effective amount.
  • monotherapy with a compound of the present invention is more effective than combination therapy in inducing a desired biological effect.
  • treating describes the management and care of a patient for the purpose of combating a disease, condition, or disorder and includes the administration of a compound of the present invention to prevent the onset of the symptoms or complications, alleviating the symptoms or complications, or eliminating the disease, condition or disorder.
  • treating cancer results in a reduction in size of a tumor. In another aspect, treating cancer results in a reduction in tumor volume. In another aspect, treating cancer results in a decrease in number of tumors. In another aspect, treating cancer results in a decrease in number of metastatic lesions in other tissues or organs distant from the primary tumor site. In another aspect, treating cancer results in an increase in average survival time of a population of treated subjects in comparison to a population receiving carrier alone. In another aspect, treating cancer results in an increase in average survival time of a population of treated subjects in comparison to a population of untreated subjects.
  • treating cancer results in increase in average survival time of a population of treated subjects in comparison to a population receiving monotherapy with a drug that is not a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof.
  • treating cancer results in a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving carrier alone.
  • treating cancer results in a decrease in the mortality rate of a population of treated subjects in comparison to an untreated population.
  • treating cancer results a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving monotherapy with a drug that is not a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof.
  • treating cancer results in a decrease in tumor growth rate.
  • treating cancer results in a decrease in tumor regrowth.
  • treating or preventing a cell proliferative disorder results in a reduction in the rate of cellular proliferation. In another aspect, treating or preventing a cell proliferative disorder results in a reduction in the proportion of proliferating cells. In another aspect, treating or preventing a cell proliferative disorder results in a decrease in size of an area or zone of cellular proliferation. In another aspect, treating or preventing a cell proliferative disorder results in a decrease in the number or proportion of cells having an abnormal appearance or morphology.
  • a compound of the present invention or a pharmaceutically acceptable salt, metabolite, analog or derivative thereof, can be administered in combination with a chemotherapeutic agent.
  • chemotherapeutic agents with activity against cell proliferative disorders are known to those of ordinary skill in the art, and may be found in reference texts such as the Physician's Desk Reference, 59th Edition, Thomson PDR (2005 ).
  • the chemotherapeutic agent can be a taxane, an aromatase inhibitor, an anthracycline, a microtubule targeting drug, a topoisomerase poison drug, a targeted monoclonal or polyclonal antibody, an inhibitor of a molecular target or enzyme (e.g., a kinase inhibitor), or a cytidine analogue drug.
  • the chemotherapeutic agent can be, but is not restricted to, tamoxifen, raloxifene, anastrozole, exemestane, letrozole, cisplatin, carboplatin, TAXOL ® (paclitaxel), cyclophosphamide, lovastatin, minosine, GEMZAR ® (gemcitabine HCl), araC, 5-fluorouracil (5-FU), methotrexate (MTX), TAXOTERE ® (docetaxel), ZOLADEX ® (goserelin), vincristin, vinblastin, nocodazole, teniposide, etoposide, epothilone, navelbine, camptothecin, daunonibicin, dactinomycin, mitoxantrone, amsacrine, doxorubicin (adriamycin), epirubicin, idarubicin
  • the chemotherapeutic agent can be a cytokine such as G-CSF (granulocyte colony stimulating factor).
  • a compound of the present invention, or a pharmaceutically acceptable salt, metabolite, analog or derivative thereof may be administered in combination with radiation therapy.
  • a compound of the present invention, or a pharmaceutically acceptable salt, metabolite, analog or derivative thereof may be administered in combination with standard chemotherapy combinations such as, but not restricted to, CMF (cyclophosphamide, methotrexate and 5-fluorouracil), CAF (cyclophosphamide, adriamycin and 5-fluorouracil), AC (adriamycin and cyclophosphamide), FEC (5-fluorouracil, epirubicin, and cyclophosphamide), ACT or ATC (adriamycin, cyclophosphamide, and paclitaxel), or CMFP (cyclophosphamide, methotrexate, 5-fluorouracil and prednisone).
  • CMF cyclophosphamide, methotrexate and 5-fluorouracil
  • CAF cyclophosphamide, adriamycin and 5-fluorouracil
  • AC ad
  • a “pharmaceutically acceptable salt” or “salt” of the disclosed compound is a product of the disclosed compound that contains an ionic bond, and is typically produced by reacting the disclosed compound with either an acid or a base, suitable for administering to a subject.
  • Pharmaceutically acceptable salt can include, but is not limited to, acid addition salts including hydrochlorides, hydrobromides, phosphates, sulphates, hydrogen sulphates, alkylsulphonates, arylsulphonates, acetates, benzoates, citrates, maleates, fumarates, succinates, lactates, and tartrates; alkali metal cations such as Na, K, Li, alkali earth metal salts such as Mg or Ca, or organic amine salts.
  • a "pharmaceutical composition” is a formulation containing the disclosed compounds in a form suitable for administration to a subject.
  • the pharmaceutical composition is in bulk or in unit dosage form.
  • the unit dosage form is any of a variety of forms, including, for example, a capsule, an IV bag, a tablet, a single pump on an aerosol inhaler, or a vial.
  • the quantity of active ingredient (e.g., a formulation of the disclosed compound or salts thereof) in a unit dose of composition is an effective amount and is varied according to the particular treatment involved.
  • active ingredient e.g., a formulation of the disclosed compound or salts thereof
  • the dosage will also depend on the route of administration.
  • routes including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, intranasal, and the like.
  • Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, bioerodable implants and inhalants.
  • the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that are required.
  • the present invention also provides pharmaceutical formulations comprising a compound of Formula I in combination with at least one pharmaceutically acceptable excipient or carrier.
  • pharmaceutically acceptable excipient or “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in " Remington: The Science and Practice of Pharmacy, Twentieth Edition," Lippincott Williams & Wilkins, Philadelphia, PA ., which is incorporated herein by reference.
  • Such carriers or diluents include, but are not limited to, water, saline, Ringer's solutions, dextrose solution, and 5% human serum albumin.
  • Liposomes and non-aqueous vehicles such as fixed oils may also be used.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
  • a compound of Formula I is administered in a suitable dosage form prepared by combining a therapeutically effective amount (e.g., an efficacious level sufficient to achieve the desired therapeutic effect through inhibition of tumor growth, killing of tumor cells, treatment or prevention of cell proliferative disorders, etc.) of a compound of Formula I (as an active ingredient) with standard pharmaceutical carriers or diluents according to conventional procedures (i.e., by producing a pharmaceutical composition of the invention). These procedures may involve mixing, granulating, and compressing or dissolving the ingredients as appropriate to attain the desired preparation.
  • a therapeutically effective amount of a compound of Formula I is administered in a suitable dosage form without standard pharmaceutical carriers or diluents.
  • Pharmaceutically acceptable carriers include solid carriers such as lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
  • Exemplary liquid carriers include syrup, peanut oil, olive oil, water and the like.
  • the carrier or diluent may include time-delay material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylate or the like.
  • Other fillers, excipients, flavorants, and other additives such as are known in the art may also be included in a pharmaceutical composition according to this invention.
  • compositions containing active compounds of the present invention may be manufactured in a manner that is generally known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.
  • Pharmaceutical compositions may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and/or auxiliaries which facilitate processing of the active compounds into preparations that can be used pharmaceutically. Of course, the appropriate formulation is dependent upon the route of administration chosen.
  • a compound or pharmaceutical composition of the invention can be administered to a subject in many of the well-known methods currently used for chemotherapeutic treatment.
  • a compound of the invention may be injected directly into tumors, injected into the blood stream or body cavities or taken orally or applied through the skin with patches.
  • systemic administration e.g., oral administration
  • topical administration to affected areas of the skin are preferred routes of administration.
  • the dose chosen should be sufficient to constitute effective treatment but not so high as to cause unacceptable side effects.
  • the state of the disease condition e.g., cancer, psoriasis, and the like
  • the health of the patient should be closely monitored during and for a reasonable period after treatment.
  • Example 1 General procedure A: Synthesis of N-(3-amino-propyl)-3-chloro-N-[( R )-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-2-fluoro-benzamide (1).
  • Example 2 General procedure A, Step 2: 2-(( R )-1-Amino-but-3-ynyl)-7-chloro-3-phenylamino-3H-quinazolin-4-one.
  • Example 3 General procedure A, Step 3: 2- ⁇ 3-[( R )-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynylamino]-propyl ⁇ -isoindole-1,3-dione.
  • Example 4 General procedure A, Step 4: 3-Chloro-N-[( R )-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-N-[3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propyl]-2-fluoro-benzamide.
  • Example 5 General procedure A. Step 5: N-(3-Amino-propyl)-3-chloro-N-[( R )-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-2-fluoro-benzamide (1).
  • Example 28 N-(3-Aminopropyl)-N-(1- ⁇ 7-chloro-3-[(3-fluorophenyl)amino]-4-oxo-3,4-dihydroquinazolin-2-yl ⁇ propyl)-4-methylbenzamide (24). (Comparative)
  • This compound was synthesized by using 2-amino-5-chloro benzoic acid instead of 2-amino-4-chloro benzoic acid as described in "general procedure A,” and, N-Boc-DL-2-amino butyric acid was used instead of ( R )- tert -butoxycarbonylamino-pent-4-ynoic acid and 4-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A.
  • LCMS m/e 505 [M+H].
  • Example 35 Synthesis of N-(3-amino-propyl)-N-[( R )-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-4-methyl-benzenesulfonamide(30).
  • Example 36 N-(3-Aminopropyl)-N-[(1 R )-1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-3-fluorobenzenesulfonamide(31). (Comparative)
  • This compound was synthesized by using O-benzyl hydroxyl amine instead of phenyl hydrazine as described in "general procedure A,” except N-Boc-DL-2-amino butyric acid was used instead of ( R )- tert -butoxycarbonylamino-pent-4-ynoic acid and 4-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A.
  • LCMS m/e 520 [M+H].
  • Example 38 N-(3-Aminopropyl)-N-[(1 R )-1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-1,3,5-trimethyl-1H-pyrazole-4-sulfonamide(33). (Comparative)
  • Example 39 N-(3-Aminopropyl)-N-[(1 R )-1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]thiophene-3-sulfonamide (34). (Comparative)
  • Example 40 N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-3-methylbutyl]-3,4-difluorobenzamide (35). (Comparative)
  • Example 48 N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-fluorobenzamide(43). (Comparative)
  • Example 50 N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-chloro-2,5-difluorobenzamide (45). (Comparative)
  • Example 54 N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-(2-thienyl)ethyl]-4-methylbenzamide(49) .
  • Example 60 N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3.4-dihydroquinazolin-2-yl)-2-(4-hydroxyphenyl)ethyl]-2,3,4-trifluorobenzamide(55). (Comparative)
  • Example 61 N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)but-3-yn-1-yl]-4-chloro-2,5-difluorobenzamide (56).
  • Example 62 N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)but-3-yn-1-yl]-3-chloro-2-fluorobenzamide (57).
  • This compound was synthesized as described in general procedure A, except beta-tert butyl-N-Boc-DL-alanine was used instead of ( R )- tert -butoxycarbonylamino-pent-4-ynoic acid and 4-bromo benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A.
  • LCMS m/e 612 [M+H].
  • Example 65 N-(2-Aminoethyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-4-chlorobenzamide (60). (Comparative)
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of ( R )- tert -butoxycarbonylamino-pent-4-ynoic acid, (1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetaldehyde was used instead of 3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propionaldehyde and 4-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A LCMS: m/e 491 [M+H].
  • Example 70 N-(2-Aminoethyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-2,3-difluoro-4-methylbenzamide (65). (Comparative)
  • Example 72 2- ⁇ ( R )-1-[(3-Amino-propyl)-(4-methyl-benzyl)-amino]-but-3-ynyl ⁇ -7-chloro-3-phenylamino-3H-quinazolin-4-one (66).
  • Example 75 2- ⁇ (1 R )-1-[(3-Aminopropyl)(4-fluoro-3-methylbenzyl)amino]propyl ⁇ -3-anilino-7-chloro-3H-quinazolin-4-one (69). (Comparative)
  • Example 76 2 ⁇ (1 R )-1-[(3-aminopropyl)(benzyl)amino]propyl ⁇ -3-anilino-7-chloro-3H-quinazolin-4-one (70). (Comparative)
  • Example 77 General Proedure D; Synthesis of ( R )-N-(3-aminopropyl)-3-chloro-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2-fluorobenzamide (1).
  • Example 78 ( R )-benzyl 3-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynylamino)propyl carbamate.
  • Example 79 ( R )-Benzyl 3-(3-chloro-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2-fluorobenzamido)propyl carbamate.
  • Example 80 ( R )-N-(3-Aminopropyl)-3-chloro-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2-fluorobenzamide (1).
  • Example 81 N-(3-Amino-pronyl)-N-[( R )-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydroquinazolin-2-yl-but-3-ynyl)-2,3,5,6-tetrafluoro-benzamide (71).
  • Example 82 ( R )-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,3,4,5-tetrafluorobenzamide (72).
  • Example 83 ( R )-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)benzo[b]thiophene-2-carboxamide (73).
  • Example 84 N-(3-Aminopropyl)-3-chloro-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)pent-3-ynyl)-2-fluorobenzamide (74).
  • Example 85 N-(3-Amino-propyl)-N-[( R )-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-4-methyl-benzamide (75).
  • Example 86 N-(3-Amino-propyl)-N-[( R )-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-2,3-difluoro-4-methyl-benzamide (76).
  • Example 87 ( R )- N -(3-Aminopropyl)- N -(1-(7-chloro-4-oxo-3-phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,3-difluoro-6-methoxybenzamide (77).
  • Example 88 ( R )- N -(3-Aminonronyl)- N -(1-(7-chloro-4-oxo-3-phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,3-difluoro-4-methoxybenzamide (78).
  • Example 90 ( R )-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-3,5-difluorobenzamide (80).
  • Example 91 ( R )-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,3,5-trifluorobenzamide (81).
  • Example 92 ( R )-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,3-difluorobenzamide (82).
  • Example 93 General procedure E: Synthesis of ( R )-N-(3-aminopropyl)-3-chloro-2-fluoro-N-(1-(4-oxo-3-(phenylamino)-3,4-dihydropyrido[3,2-d]pyrimidin-2-yl)but-3-ynyl)benzamide (83).
  • Example 94 ( R )- tert -butyl 1-(4-oxo-3-(phenylamino)-3,4-dihydropyrido[3,2-d]pyrimidin-2-yl)but-3-ynylcarbamate.
  • Example 96 ( R )-Benzyl 3-(1-(4-oxo-3-(phenylamino)-3,4-dihydropyrido[3,2-d]pyrimidin-2-yl)but-3-ynylamino)propylcarbamate.
  • Example 98 ( R )-N-(3-Aminopropyl)-3-chloro-2-fluoro-N-(1-(4-oxo-3-(phenylamino)-3, 4- dihydropyrido[3,2-d]pyrimidin-2-yl)but-3-ynyl)benzamide (83).
  • Example 99 ( R )-N-(3-Aminopropyl)-2,3-difluoro-4-methyl-N-(1-(4-oxo-3-(phenylamino)-3,4-dihydropyrido[3,2-d]pyrimidin-2-yl)but-3-ynyl)benzamide (84).
  • Example 100 ( R )-N-(3-Aminopropyl)-2,6-difluoro-3-methyl-N-(1-(4-oxo-3-(phenylamino)-3,4-dihydropyrido[3,2-d]pyridin-2-yl)but-3-ynyl)benzamide (85).
  • Example 101 ( R )-N-(3-Aminopropyl)-2,3,4,5-tetrafluoro-N-(1-(4-oxo-3-(phenylamino)-3,4-dihydropyrido[3,2-d]pyrimidin-2-yl)but-3-ynyl)benzamide (86).
  • Example 102 Fluorescence detection of HsEg5 ATPase activity and compound inhibition
  • a standard curve was determined using the provided ADP reagent in the reaction buffer that consisted of 50 mM Pipes (pH7.0), 5.0 mM MgCl 2 , 20 ⁇ M paclitaxel and 0.5 ⁇ M tubulin. The same buffer was used for K m determination with Hs Eg5 concentration of 10 nM.
  • Hs Eg5 For inhibitor screening, 4 ⁇ L of compounds were incubated with 10 ⁇ L of MT-activated Hs Eg5 such that the final concentrations for compound range from 100 ⁇ M to 5 nM (1 to 3 serial dilutions, final concentration) and final concentration for Hs Eg5 is 10 nM. The mixture was incubated at room temperature for 10 minutes with mild shaking.
  • the screening assay contained 0.3% DMSO in all reaction wells. We used wells containing only DMSO as negative controls and wells without ATP as background. Addition of 6 ⁇ L ATP (final concentration of 20 ⁇ M) initiated the ATP hydrolysis reaction.
  • Example 103 Robotic settings for high-throughput screening
  • the mother compound plate contained 24 ⁇ L of tested compound at stock concentration of 30 mM. 6 ⁇ L of each test compound in 30 mM was added to each well in the column 2 and followed by 1:3 serial dilutions in DMSO with the Sciclone ALH3000. 234 ⁇ L of assay buffer was then added using a Multidrop 384. Then 4 ⁇ L of diluted compounds was used in 20 ⁇ L-reaction. The final concentration was a 1:300 dilution of the original stock. Second, a reagent source plate was prepared with three rows designated to MT-activated Hs Eg5, Reagent A and Reagent B respectively.
  • MTs were diluted with assay buffer and polymerized at room temperature for 10 minutes. Just before use, Hs Eg5 protein was thawed on ice and activated by addition of MT polymers at room temperature for 20 minutes. Hs Eg5/MT was then added to Row A of the reagent source plate. The final assay concentration was 10 nM Hs Eg5 and 500 nM MTs. Reagent A and B were stored at -20°C and thawed at room temperature followed by transferring to rows B & C of the reagent source plate.
  • ATP substrate plate was prepared by transferring 80 ⁇ M ATP solution to each well of a V-shape 96-well plate except the wells in the first row where assay buffer was added instead to have no-ATP blanks.
  • the final concentration for ATP in the assay was 20 ⁇ M.
  • the assay was programmed on Sciclone ALH3000 with the following procedures: 1) Addition of 4 ⁇ L compounds to the assay plate, followed by addition of 10 ⁇ L of MT-activated Hs Eg5. The mixture was incubated at room temperature for 10 minutes with occasionally shaking; 2) Hs Eg5 ATPase reaction was initiated by addition of 6 ⁇ L of ATP and proceeded at room temperature for 10 minutes. 3) Addition of 10 ⁇ L reagent A and 20 ⁇ L reagent B to the plate and incubation at room temperature for exactly 20 minutes. The fluorescence was measured at Wallac Victor 2 multilabel counter with excitation and emission wavelength stated previously.
  • Example 104 Luminescent detection of HsEg5 ATPase activity and compound inhibition
  • Hs Eg5 motor fragment was activated by mixture with preformed MT polymer (Cytoskeleton, Denver, CO) at room temperature for 20 minutes.
  • MT activated ATPase activity was measured using Kinase-Glo® Plus Luminescent Kinase Assay (Promega, Madison, WI).
  • Hs Eg5 For inhibitor screening, 5 ⁇ L of compounds were incubated with 20 ⁇ L of MT-activated Hs Eg5 such that the final concentrations for compound range from 100 ⁇ M to 5 nM (1 to 3 serial dilutions, final concentration) and final concentration for Hs Eg5 is 25 nM. The mixture was incubated at room temperature for 20 minutes with mild shaking.
  • the screening assay contained 0.3% DMSO in all reaction wells. We used wells containing only DMSO as negative controls and wells without ATP as background. Addition of 15 ⁇ L of 13 ⁇ M ATP (final concentration of 5 ⁇ M) initiated the ATP hydrolysis reaction. The 40 ⁇ L-reaction was allowed to proceed at room temperature for 45 minutes before addition of 40 ⁇ L of Kinase®-Glo Plus. After 15-minute development at room temperature, the luminescent was measured.
  • Cell viability was determined by measuring the activity of dehydrogenase enzymes in metabolically active cells using a tetrazolium compound, MTS. The assay was performed as described in Promega Technical Bulletin No. 169 (CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay). Two human cancer cell lines were assayed ( see. Table 1). Cells were maintained at 37°C and 5% CO 2 in DMEM media (4.5 g/L glucose) supplemented with 10% heat-inactivated FBS, 10 mM L-glutamine, and 10 mM Hepes pH 7.5. Briefly, cells were seeded in 96-well plates as set forth in Table 1 and incubated for 16-24 hours.
  • Candidate compounds were serially diluted in DMSO, further diluted in cell culture media, and then added to cells (final DMSO concentration of 0.33%). Cells were incubated in the presence of candidate compound for 72 hours. MTS stock solution (MTS 2 gm/L, PMS 46.6 mg/ml in PBS) was added to the cells (final concentration MTS 2 gm/L and PMS 7.67 mg/L) and incubated for 4 hours. SDS was added to a final concentration of 1.4% and absorbance at 490 nM was measured within two hours using a plate reader.
  • MTS stock solution MTS 2 gm/L, PMS 46.6 mg/ml in PBS
  • SDS was added to a final concentration of 1.4% and absorbance at 490 nM was measured within two hours using a plate reader.
  • the IC 50 was defined as the concentration of compound that results in a 50% reduction in the number of viable cells as compared to control wells treated with DMSO only (0.33%) and was calculated using non-linear regression analysis. IC 50 values were given in Table 2 for the compounds listed. The Compound Numbers in Table 2 correspond to the numbers listed parenthetically in the Example titles.
  • Example 106 In vivo Data
  • Athymic nude mice Six-week old female athymic nude mice (NCR nu/nu; Charles River Laboratory, Wilmington, MA) were acclimated to the animal housing facility for at least 1 week before the study. Efficacy studies were performed in athymic mice bearing PACA2 tumor xenografts to determine the effect of compound on tumor growth. Tumor cells (1 ⁇ 10 7 PACA2 cells/animal) were inoculated subcutaneously on day 0. Tumor dimensions were measured by a digital microcaliper, and tumor volumes were calculated as length ⁇ width 2 / 2.
  • Example 107 In vivo Data
  • mice Six weeks old female athymic nude mice (NCR nu/nu) received from Charles River Laboratory, acclimated to the animal housing facility for one week before initiation of the study. Mice were housed in sterile cages of 4 each with autoclaved bedding, provided with autoclaved food and water ad libitum. Efficacy studies were performed in athymic mice bearing PACA2 tumor xenografts to determine the effect of compound on tumor growth. Tumor cells (1 ⁇ 10 7 PACA2 cells/animal) were inoculated subcutaneously on day 0. Tumor dimensions were measured three times weekly by a digital microcaliper, and tumor volumes were calculated as length ⁇ width 2 /2.
  • Example 108 In vivo Data
  • mice Six weeks old female athymic nude mice (NCR nu/nu) received from Charles River Laboratory, acclimated to the animal housing facility for one week before initiation of the study. Mice were housed in sterile cages of 4 each with autoclaved bedding, provided with autoclaved food and water ad libitum. Efficacy studies were performed in athymic mice bearing MDA-MB-231 tumor xenografts to determine the effect of compound on tumor growth. Tumor cells (5 ⁇ 10 6 MDA-MB-231 cells/animal) were inoculated subcutaneously on day 0. Tumor dimensions were measured three times weekly by a digital microcaliper, and tumor volumes were calculated as length ⁇ width 2 /2.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

    BACKGROUND OF THE INVENTION
  • Cancer is the second leading cause of death in the United States, exceeded only by cardiovascular disease. (Cancer Facts and Figures 2005, American Cancer Society, Inc.) Despite recent advances in cancer diagnosis and treatment, surgery and radiotherapy may be curative if a cancer is found early, but current drug therapies for metastatic disease are by and large only palliative and seldom offer a long-term cure. Even with new chemotherapies entering the market, the need continues for effective new drugs used either in monotherapy or in combination with existing agents as first line therapy, and as second and third line therapies in treatment of resistant tumors.
  • Improving the specificity of agents used to treat cancer is of considerable interest because of the therapeutic benefits which would be realized if the side effects associated with the administration of these agents could be reduced. One approach for cancer treatment is targeting mitotic processes of mammalian cells. Examples of the therapeutic agents targeting mitosis include the taxanes, and the camptothecin class of topoisomerase I inhibitors.
  • An emerging target class for cancer treatment is mitotic kinesins. Mitotic kinesins are enzymes essential for assembly and function of the mitotic spindle, but are not generally part of other microtubule structures, such as in nerve processes. Mitotic kinesins play an essential role during all phases of mitosis. These enzymes are "molecular motors" that transform energy released by hydrolysis of ATP into mechanical force which drives the directional movement of cellular cargoes along microtubules. The catalytic domain sufficient for this task is a compact structure of approximately 340 amino acids. During mitosis, kinesins organize microtubules into the bipolar structure that is the mitotic spindle. Kinesins mediate movement of chromosomes along spindle microtubules, as well as structural changes in the mitotic spindle associated with specific phases of mitosis. Experimental perturbation of mitotic kinesin function causes malformation or dysfunction of the mitotic spindle, frequently resulting in cell cycle arrest and cell death.
  • Among the mitotic kinesins which have been identified is KSP (also termed Eg5). KSP belongs to an evolutionarily conserved kinesin subfamily of plus-end-directed microtubule motors that assemble into bipolar homotetramers consisting of antiparallel homodimers. During mitosis KSP associates with microtubules of the mitotic spindle. Microinjection of antibodies directed against KSP into human cells prevents spindle pole separation during prometaphase, giving rise to monopolar spindles and causing mitotic arrest and induction of programmed cell death. KSP and related kinesins in non-human organisms bundle antiparallel microtubules and slide them relative to one another, thus forcing the two spindle poles apart. KSP may also mediate anaphase B spindle elongation and focusing of microtubules at the spindle pole.
  • Human KSP (also termed HsEg5) has been described [Blangy, et al., Cell, 83:1159-69 (1995); Whitehead, et al., Arthritis Rheum., 39:1635-42 (1996); Galgio et al., J. Cell Biol., 135:339-414 (1996); Blangy, et al., J. Biol. Chem., 272:19418-24 (1997); Blangy, et al., Cell Motil Cytoskeleton, 40:174-82 (1998); Whitehead and Rattner, J. Cell Sci., 111:2551-61 (1998); Kaiser, et al., JBC 274:18925-31 (1999); GenBank accession numbers: X85137, NM004423 and U37426], and a fragment of the KSP gene (TRIP5) has been described [Lee, et al., Mol Endocrinol., 9:243-54 (1995); GenBank accession number L40372]. Xenopus KSP homologs (Eg5), as well as Drosophila K-LP61 F/KRP 130 have been reported.
  • Certain quinazolinones have been recently described as being inhibitors of KSP [PCT Publ. WO 01/30768, May 3, 2001 ; PCT Publ. WO 01/98278, Dec 27, 2001 ; PCT Publ. WO 01/30768, May 3, 2001 ; PCT Publ. WO 03/039460, May 15, 2003 ; PCT Publ. WO 03/043995, May 30 2003 ; PCT Publ. WO 03/070701, August 28, 2003 ; PCT Publ. WO 03/097053, Nov 27, 2003 ; PCT Publ. WO 03/103575, December 18, 2003 ; PCT Publ. WO 04/39 774, May 13, 2004 and PCT Publ. WO 04/009036, January 29, 2004 .].
  • Quinazolinone derivatives are privileged structures present in many biologically active compounds such methaqualone, a sedative-hypnotic agent, chloroqualone, an antitussive agent, and piriqualone, an anticonvulsant. It has been known that quinazolinones and derivatives have a wide variety of biological properties such as hypnotic, analgesic, anticonvulsant, antitussive and anti-inflammatory activities.
  • Quinazolinone derivatives for which specific biological uses have been described include U.S. Patent No. 5,147875 describing 2-(substituted phenyl)-4-oxoquinazolines with bronchodilator activity is described. U.S. Patent Nos. 3,723,432 , 3,740,442 , and 3,925,548 describe a class of 1-substituted-4-aryl-2(1H)-quinazolinone derivatives useful as anti-inflammatory agents. European patent publication EP 0 056 637 B1 claims a class of 4(3H)-quinazolinone derivatives for treating hypertension. European patent publication EP 0 884 319 A1 describes pharmaceutical compositions of quinazolin-4-one derivatives used for the treatment of neurodegenerative, psychotropic, and drug and alcohol induced central and peripheral nervous system disorders.
  • Quinazolinone derivatives are one of a growing list of therapeutic agents used for the treatment of cellular proliferate disorders, including cancer. In this area, for example, PCT WO 96/06616 describes a pharmaceutical composition containing a quinazolinone derivative to inhibit vascular smooth cell proliferation. PCT WO 96/19224 uses this same quinazolinone derivative to inhibit mesangial cell proliferation. U.S. Patent Nos. 4,981,856 , 5,081,124 , and 5,280,027 describes the use of quinazolinone derivatives to inhibit thymidylate synthase, the enzyme that catalyzes the methylation of deoxyuridine monophosphate to produce thymidine monophosphate which is required for DNA synthesis. U.S. Patent Nos. 5,747,498 and 5,773,476 describes quinazolinone derivatives used for the treatment of cancer characterized by over-activity or inappropriate activity of tyrosine receptor kinase. U.S. Patent No. 5,037,829 claims (1H-azol-1-ylmethyl) substituted quinazoline compositions for the treatment of carcinomas that occur in epithelial cells. PCT WO 98/34613 describes a composition containing a quinazolinone derivative useful for attenuating neovascularization and for treating malignancies. U.S. Patent 5,187,167 describes pharmaceutical compositions comprising quinazolin-4-one derivatives that possess antitumor activity.
  • The references cited herein are not admitted to be prior art to the claimed invention.
    • SUMMARY OF THE INVENTION
  • The present invention provides a compound of formula I, or pharmaceutically acceptable salts thereof:
    Figure imgb0001
  • Wherein
    m, n and A are independently selected from the group consisting of 0, 1, 2, 3, and 4.
    R1 is selected from the group consisting of H, alkyl, aryl, substituted aryl , haloaryl, biaryl, or bis-aryl, alkenyl, alkynyl, heteroaryl, cycloalkyl, heterocyclyl, haloalkyl, and perfluoroalkyl;
    Y is selected from the group consisting of a bond, -C=O, -S=O, and -S(O)2;
    X is selected from the group consisting of NR2, O, S and CHR2; R1 and R2, taken together, may form a ring; and
    R2 is selected from the group consisting of hydrogen, alkyl including lower alkyl, aryl, alkenyl, alkynyl, heteroaryl, alkylheteroaryl, cycloalkyl, heterocyclyl, and perfluoroalkyl;
    R3 is selected from H, alkyl, aryl, alkylaryl, heteroaryl, perfluoroalkyl, alkenyl, and alkynyl,;
    R4 is alkenyl; and
    Each R5 and each R6 are independently selected from the group consisting of H, halogen, hydroxyl, nitrogen, amino, cyano, alkoxy, alkylthio, methylenedioxy, or haloalkyloxy; or alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylamino, dialkylamino, alkylsulfonyl, arylsulfonyl, alkylcarboxy, carboxyamino, carboxyamido, aminocarbonyl, and alkylsulfonamido;
    Q is either absent or selected from the group consisting of -CO-, -COO-, -CONR11, -C(=S)-, -CH2-, -SO-, and -SO2-;
    R7 is selected from the group consisting of hydrogen, alkyl, aryl, alkylaryl, heteroaryl, aryls substituted with heterocycles;
    W is selected from H or NR8R9; where R8 and R9 are independently selected from the group consisting of hydrogen, alkyl; aryl, heteroaryl, alkenyl, alkynyl, COR13, -CO2R13; - CONR14R14, -SOR13, -SO2R13, -C(=S)R14, -C(=NH)R14, -C(=O)NR15R15, and - C(=S)NR14R15, or R8 and R9 together with the N they are bonded to optionally form a heterocycle or substituted heterocycle;
  • Each Z is C.
  • Each R10 is independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, amino, cyano, alkoxy, alkylthio, methylenedioxy, or haloalkyloxy; alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylamino, dialkylamino, alkylsulfonyl, arylsulfonyl, alkylcarboxy, carboxyamino, carboxyamido, aminocarbonyl, and alkylsulfonamido;
    R11, R12, R13, R14, and R15 are independently selected from the group consisting of hydrogen, alkyl, aryl, alkylaryl, heteroaryl, oxaalkyl, oxaalkylaryl, and substituted oxaalkylaryl.
  • In an embodiment, the stereochemistry of the compound is of "R" configuration.
  • The present invention also provides a pharmaceutical composition comprising a compound of formula I in combination with a pharmaceutically acceptable carrier or excipient. In an embodiment, the pharmaceutical composition further comprises a second chemotherapeutic agent.
  • The present invention further provides compounds for use in a method of treating a cell proliferative disorder. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, or a prodrug or metabolite thereof, in combination with a pharmaceutically acceptable carrier, wherein said cell proliferative disorder is treated.
  • In an embodiment, the cell proliferative disorder is a precancerous condition. In another embodiment, the cell proliferative disorder is a cancer. In a further embodiment, the cancer is adenocarcinoma, squamous carcinoma, sarcoma, lymphoma, multiple myeloma, or leukemia. Alternatively, the cancer is lung cancer, colon cancer, breast cancer, pancreatic cancer, prostate cancer, acute leukemia, chronic leukemia, multiple melanoma, ovarian cancer, malignant glioma, leiomyosarcoma, hepatoma, or head and neck cancer. The cancer can be primary cancer or metastatic cancer.
  • In an embodiment, the compound of formula I, or a pharmaceutically acceptable salt thereof, is administered in combination with a second chemotherapeutic agent.
  • Other features and advantages of the present invention are apparent from the additional descriptions provided herein including the different examples. The provided examples illustrate different components and methodology useful in practicing the present invention. The examples do not limit the claimed invention. Based on the present disclosure the skilled artisan can identify and employ other components and methodology useful for practicing the present invention.
    • BRIEF DESCRIPTION OF THE DRAWINGS
    • Figure 1A and 1B shows the effect of N-(3-amino-propyl)-3-chloro-N-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-2-fluoro-benzamide on PACA-2 xenograft model.
    • Figure 2 shows the effect of N-(3-amino-propyl)-3-chloro-N-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-2-fluoro-benzamide on MDA-MB-231 xenograft model.
    DETAILED DESCRIPTION OF THE INVENTION
  • This invention relates to quinazolinone derivatives. In an embodiment, the compounds of the present invention are inhibitors of mitotic kinesins, the mitotic kinesin KSP in particular. In a further embodiment, the compounds of the present invention are useful for treating cellular proliferative diseases including cancer.
    • 1. Aryl quinazolinone derivatives
  • The present invention relates to new aryl quinazolinone derivatives, their pharmaceutically acceptable salts and stereoisomers that can be used to treat cellular proliferative diseases, disorders associated with KSP kinesin activity, and inhibit KSP kinesin.
  • In one embodiment, the aryl quinazolinone derivatives are compounds of formula I, or pharmaceutically acceptable salts thereof:
    Figure imgb0002
  • Wherein
    m, n and A are independently selected from the group consisting of 0, 1, 2, 3, and 4.
    R1 is selected from the group consisting of H, alkyl, aryl, substituted aryl, haloaryl, bi aryl, or bis aryl, alkenyl, alkynyl, heteroaryl, cycloalkyl, heterocyclyl, haloalkyl, and perfluoroalkyl;
    Y is selected from the group consisting of a bond, -C=O, -S=O, and -S(O)2;
    X is selected from the group consisting of NR2, O, S and CHR2; R1 and R2, taken together, may form a ring; when X is CHR2, R4 is alkynyl, or alkenyl;
    R2 is selected from the group consisting of hydrogen, alkyl including lower alkyl, aryl, alkenyl, alkynyl, heteroaryl, alkylheteroaryl, cycloalkyl, heterocyclyl, and perfluoroalkyl;
    R3 is selected from H, alkyl, aryl, alkylaryl, heteroaryl, perfluoroalkyl, alkenyl, and alkynyl;
    R4 is alkynyl;
    Each R5 and each R6 are independently selected from the group consisting of H, halogen, hydroxyl, nitrogen, amino, cyano, alkoxy, alkylthio, methylenedioxy, or haloalkyloxy; or alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylamino, dialkylamino, alkylsulfonyl, arylsulfonyl, alkylcarboxy, carboxyamino, carboxyamido, aminocarbonyl, and alkylsulfonamido;
    Q is either absent or selected from the group consisting of-CO, -COO, -CONR11, - C(=S), -CH2, -SO, and -SO2;
    R7 is selected from the group consisting of hydrogen, alkyl, aryl, alkylaryl, heteroaryl, aryls substituted with heterocycles;
    W is selected from H or NR8R9; where R8 and R9 are independently selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, alkenyl, akynyl, COR13, -CO2R13, - CONR14R14, -SOR13, -SO2R13, -C(=S)R14, -C(=NH)R14, -C(=O)NR15R15, and - C(=S)NR14R15; or R8 and R9 together with the N they are bonded to optionally form a heterocycle or substituted heterocycle;
  • Each Z is independently selected from the group consisting of N, and C; m is 0 when Z is N.
    Each R10 is independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, amino, cyano, alkoxy, alkylthio, methylenedioxy, or haloalkyloxy; alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylamino, dialkylamino, alkylsulfonyl, arylsulfonyl, alkylcarboxy, carboxyamino, carboxyamido, aminocarbonyl, and alkylsulfonamido;
    R11, R12, R13, R14, and R15 are independently selected from the group consisting of hydrogen, alkyl, aryl, alkylaryl, heteroaryl, oxaalkyl, oxaalkylaryl, and substituted oxaalkylaryle.
  • In an embodiment, A is 0, 1, or 2.
  • In an embodiment, A is 1, and R5 and R6 are H.
  • In an embodiment, m is 1.
  • In an embodiment, n is 3.
  • In an embodiment, n is 2.
  • In an embodiment, R8 and R9 are H.
  • In an embodiment, X is NR2. In a further embodiment, X is NH2. In an alternative embodiment, X is O or S.
  • In another embodiment, X is CHR2. In a further embodiment, X is ethynyl.
  • In an embodiment, Y is a bond.
  • In an embodiment, R1 is phenyl.
  • In an embodiment, R2 is H.
  • In an embodiment, R3 is H.
  • In an embodiment, R4 is ethynyl.
  • In an embodiment, R5 and R6 are H.
  • In an embodiment, Q is absent.
  • In an embodiment, Q is CO, CH2, CHR12, or SO2.
  • In an embodiment, R7 is unsubstituted or substituted phenyl.
  • In an embodiment W is H.
  • In an embodiment, R8 and R9 are H.
  • Some representative compounds of Formula I are shown as follows: N-(3-Amino-propyl)-3-chloro-N-[(R)- 1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-2-fluoro-benzamide,
    2-{(R)-1-[(3-Amino-propyl)-(4-methylbenzyl)-amino]-but-3-ynyl}-7-chloro-3-phenylamino-3H-quinazolin-4-one,
    N-(3-Amino-propyl)-N-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-4-methyl-benzenesulfonamide,
    N-(3-Amino-propyl)-N-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydroquinazolin-2-yl-but-3-ynyl]-2,3,5,6-tetrafluoro-benzamide, (R)-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,3,4,5-tetrafluorobenzamide, N-(3-Aminopropyl)-3-chloro-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)pent-3-ynyl)-2-fluorobenzamide, N-(3-Amino-propyl)-N-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-2,3-difluoro-4-methyl-benzamide, (R)-N-(3-Aminopropyl)-N-( 1-(7-chloro-4-oxo-3-phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,3-difluoro-6-methoxybenzamide, (R)-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,3-difluoro-4-methoxybenzamide, (R)-N-(3-Aminopropyl)-4-chloro-N-(1-(7-chloro-4-oxo-3-phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,6-difluoro-benzamide, (R)-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-3,5-difluorobenzamide, (R)-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,3,5-trifluorobenzamide, (R)-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,3-difluorobenzamide.
  • Representative compounds of the present invention are also shown in the Examples.
  • As used in this description and the accompanying claims, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs unless defined otherwise. In case of a conflict in terminology, the present specification controls. The following terms generally have the following meanings.
  • As used herein, the term "alkyl" includes saturated aliphatic groups, including straight-chain alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl), branched-chain alkyl groups (e.g., isopropyl, tert-butyl, isobutyl). "Alkyl" further includes alkyl groups that have oxygen, nitrogen, or sulfur atoms replacing one or more hydrocarbon backbone carbon atoms. In certain embodiments, a straight chain or branched alkyl has six or fewer carbon atoms in its backbone (e.g., C1-C6 for straight chain, C3-C6 for branched chain), and more preferably four or fewer.
  • The term "alkyl" also includes both "unsubstituted" and "substituted alkyls", the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbon of the hydrocarbon backbone. Such substituents can include, for example, alkyl, alkenyl, alkynyl, hydroxyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxyacid, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl, and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl (S(O)2NH2), aminesulfoxide (NHS(O) or S(O)NH), sulfonamide (NHS(O)2 or S(O)2NH), nitro, -CF3, halogen, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. An "alkylaryl" or aralkyl moiety is an alkyl moiety substituted with an aryl (e.g., methylphenyl (benzyl)). "Alkyl" also includes the side chains of natural and unnatural amino acids.
  • Aryl includes groups with aromaticity, including 5- and 6-membered "unconjugated", or single-ring aromatic groups that may include from one to four heteroatoms, as well as "conjugated", or multicyclic systems with at least one aromatic ring. Examples of aryl groups include phenyl, pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like. Furthermore, the term "aryl" includes multicyclic groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, naphthidine, indole, benzofuran, purine, benzofuran, deazapurine, or indolizine. Those aryl groups having heteroatoms in a ring structure may also be referred to as "aryl heterocycles", "heterocycles", "heterocyclyls", "heteroaryls" or "heteroaromatics" e.g., pyridine, pyrazole, pyrimidine, furan, isoxazole, imidazole[2, l,b]thiazole, triazole, pyrazine, benzothiophene, imidazole, or thiophene.
  • The aryl ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxyacid, alkylcarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, carboxyalkyl, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Aryl groups can also be fused or bridged with alicyclic or heterocyclic rings, which are not aromatic so as to form a multicyclic system (e.g., tetralin, methylenedioxyphenyl).
  • "Alkenyl" includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double bond. For example, the term "alkenyl" includes straight-chain alkenyl groups (e.g., ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl), branched-chain alkenyl groups, cycloalkenyl (e.g., alicyclic) groups (e.g., cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl groups, and cycloalkyl or cycloalkenyl substituted alkenyl groups. The term "alkenyl" further includes alkenyl groups, which include oxygen, nitrogen, or sulfur replacing one or more hydrocarbon backbone carbons. In certain embodiments, a straight chain or branched chain alkenyl group has six or fewer carbon atoms in its backbone (e.g.. C2-C6 for straight chain, C3-C6 for branched chain.) Likewise, cycloalkenyl groups may have from three to eight carbon atoms in their ring structure, and more preferably have five or six carbons in the ring structure. The term "C2-C6" includes alkenyl groups containing two to six carbon atoms.
  • The term "alkenyl" also includes both "unsubstituted alkenyls" and "substituted alkenyls", the latter of which refers to alkenyl moieties having substituents replacing a hydrogen on one or more hydrocarbon backbone carbon atoms. Such substituents can include, for example, alkyl groups, alkenyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxyacid, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, phenyl, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
  • "Alkynyl" includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond. For example, "alkynyl" includes straight chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl), branched chain alkynyl groups, and cycloalkyl or cycloalkenyl substituted alkynyl groups. The term "alkynyl" further includes alkynyl groups having oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more hydrocarbon backbone carbons. In certain embodiments, a straight chain or branched chain alkynyl group has six or fewer carbon atoms in its backbone (e.g.. C2-C6 for straight chain, C3-C6 for branched chain). The term "C2-C6" includes alkynyl groups containing two to six carbon atoms.
  • The term "alkynyl" also includes both "unsubstituted alkynyls" and "substituted alkynyls", the latter of which refers to alkynyl moieties having substituents replacing a hydrogen on one or more hydrocarbon backbone carbon atoms. Such substituents can include, for example, alkyl groups, alkenyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxyacid, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
  • Unless the number of carbons is otherwise specified, "lower alkyl" includes an alkyl group, as defined above, but having from one to ten, more preferably from one to six, carbon atoms in its backbone structure. "Lower alkenyl" and "lower alkynyl" have chain lengths of, for example, 2-5 carbon atoms.
  • As used herein, "amine" or "amino" includes compounds where a nitrogen atom is covalently bonded to at least one carbon or heteroatom. "Alkylamino" includes groups of compounds wherein nitrogen is bound to at least one additional alkyl group. Examples of alkylamino groups include benzylamino, methylamino, ethylamino, and phenethylamino. "Dialkylamino" includes groups wherein the nitrogen atom is bound to at least two additional alkyl groups. Examples of dialkylamino groups include dimethylamino and diethylamino. "Arylamino" and "diarylamino" include groups wherein the nitrogen is bound to at least one or two aryl groups, respectively. "Alkylarylamino," "alkylaminoaryl" or "arylaminoalkyl" refers to an amino group which is bound to at least one alkyl group and at least one aryl group. "Alkaminoalkyl" refers to an alkyl, alkenyl, or alkynyl group bound to a nitrogen atom which is also bound to an alkyl group.
  • The term "amide" or "aminocarboxy" includes compounds or moieties that contain a nitrogen atom that is bound to the carbon of a carbonyl or a thiocarbonyl group. The term includes "alkaminocarboxy" groups that include alkyl, alkenyl, or alkynyl groups bound to an amino group bound to a carboxy group. It includes arylaminocarboxy groups that include aryl or heteroaryl moieties bound to an amino group that is bound to the carbon of a carbonyl or thiocarbonyl group. The terms "alkylaminocarboxy," "alkenylaminocarboxy," "alkynylaminocarboxy," and "arylaminocarboxy" include moieties wherein alkyl, alkenyl, alkynyl and aryl moieties, respectively, are bound to a nitrogen atom which is in turn bound to the carbon of a carbonyl group. Amides can be substituted with substituents such as straight chain alkyl, branched alkyl, cycloalkyl, aryl, heteroaryl, or heterocycle. Substituents on amide groups may be further substituted.
  • "Acyl" includes compounds and moieties that contain the acyl radical (CH3CO-) or a carbonyl group. "Substituted acyl" includes acyl groups where one or more of the hydrogen atoms are replaced by for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxyacid, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
  • "Acylamino" includes moieties wherein an acyl moiety is bonded to an amino group. For example, the term includes alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido groups.
  • The term "alkoxy" or "alkoxyl" includes substituted and unsubstituted alkyl, alkenyl, and alkynyl groups covalently linked to an oxygen atom. Examples of alkoxy groups (or alkoxyl radicals) include methoxy, ethoxy, isopropyloxy, propoxy, butoxy, and pentoxy groups. Examples of substituted alkoxy groups include halogenated alkoxy groups. The alkoxy groups can be substituted with groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxyacid, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moieties. Examples of halogen substituted alkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, and trichloromethoxy.
  • The term "cycloalkyl" includes saturated acyclic groups (e.g., cyclopropyl, cyclopentyl, cyclohexyl, cyclohexyl, cycloheptyl, cyclooctyl). Preferred cycloalkyls have from three to eight carbon atoms in their ring structure, and more preferably have five or six carbon atoms in the ring structure. Cycloalkyls includes both "unsubstituted cycloalkyls" and "substituted cycloalkyls", the latter of which refers to replacing a hydrogen on one or more of the carbons in the ring structure. Such substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxyacid, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
  • The terms "heterocyclyl" or "heterocyclic group" include closed ring structures, e.g., 3-to 10-, or 4- to 7-membered rings, which include one or more heteroatoms. "Heteroatom" includes atoms of any element other than carbon or hydrogen. Examples of heteroatoms include nitrogen, oxygen, or sulfur.
  • Heterocyclyl groups can be saturated or unsaturated and include pyrrolidine, pyrazine, pyrimidine, oxolane, 1,3-dioxolane, thiolane, tetrahydrofuran, tetrahydropyran, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams such as azetidinones and pyrrolidinones, sultams, and sultones. Heterocyclic groups such as pyrrole and furan can have aromatic character. They include fused ring structures such as quinoline and isoquinoline. Other examples of heterocyclic groups include pyridine and purine. The heterocyclic ring can be substituted at one or more positions with such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxyacid, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, or an aromatic or heteroaromatic moiety. Heterocyclic groups can also be substituted at one or more constituent atoms with, for example, a lower alkyl, a lower alkenyl, a lower alkoxy, a lower alkylthio, a lower alkylamino, a lower alkylcarboxyl, a nitro, a hydroxyl, -CF3, or -CN, or the like.
  • The term "thioalkyl" includes compounds or moieties which contain an alkyl group connected with a sulfur atom. The thioalkyl groups can be substituted with groups such as alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxyacid, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moieties.
  • The term "carbonyl" or "carboxy" includes compounds and moieties which contain a carbon connected with a double bond to an oxygen atom. Examples of moieties containing a carbonyl include, but are not limited to, aldehydes, ketones, carboxylic acids, amides, esters, anhydrides, etc.
  • The term "thiocarbonyl" or "thiocarboxy" includes compounds and moieties which contain a carbon connected with a double bond to a sulfur atom.
  • The term "hydroxy" or "hydroxyl" includes groups with an -OH or -O-.
  • The term "halogen" includes fluorine, bromine, chlorine, iodine, etc. The term "perhalogenated" generally refers to a moiety wherein all hydrogens are replaced by halogen atoms.
  • The term "C1-C6" includes one to six carbon atoms (C1, C2, C3, C4, C5 or C6). The term "C2-C6" includes two to six carbon atoms (C2, C3, C4, C5 or C6). The term "C3-C6" includes three to six carbon atoms (C3, C4, C5 or C6). The term "C3-C8" includes three to eight carbon atoms (C3, C4, C5, C6, C7 or C8). The term "C5-C8" includes five to eight carbon atoms (C5, C6, C7 or C8).
  • It should be noted that any heteroatom or carbon atom with unsatisfied valences is assumed to have the hydrogen atom to satisfy the valences.
  • The compounds described herein may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic, and geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. All tautomers of shown or described compounds are also considered to be part of the present invention.
  • It is to be understood accordingly that the isomers arising from such asymmetry (e.g., all enantiomers and diastereomers) are included within the scope of the invention, unless indicated otherwise. Such isomers can be obtained in substantially pure form by classical separation techniques and by stereochemically controlled synthesis. Furthermore, the structures and other compounds and moieties discussed in this application also include all tautomers thereof. Alkenes can include either the E- or Z-geometry, where appropriate.
  • The term "substituted," as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto(i.e., =O), then 2 hydrogens on the atom are replaced. Keto substituents are not present on aromatic moieties. Ring double bonds, as used herein, are double bonds that are formed between two adjacent ring atoms (e.g., C=C, C=N, or N=N). "Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom in the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible, but only if such combinations result in stable compounds.
  • In the specification, the singular forms also include the plural, unless the context clearly dictates otherwise.
    • 2. The Synthesis of Compounds
  • The present invention also provides methods for the synthesis of the compounds of Formula I. In one embodiment, the present invention provides a method for the synthesis of compounds according to the following schemes, and the protocols shown in the Examples.
  • Throughout the description, where compositions are described as having, including, or comprising specific components, it is contemplated that embodiments of the compositions may also consist essentially of, or consists of, the recited components. Similarly, where methods or processes are described as having, including, or comprising specific process steps, the processes may also include embodiments that consist essentially of, or consist of, the recited processing steps. Further, it should be understood that the order of steps or order for performing certain actions is immaterial so long as the invention remains operable. Moreover, two or more steps or actions can be conducted simultaneously.
  • The synthetic processes of the invention can tolerate a wide variety of functional groups, therefore various substituted starting materials can be used. The processes generally provide the desired final compound at or near the end of the overall process, although it may be desirable in certain instances to further convert the compound to a pharmaceutically acceptable salt, ester, or prodrug thereof.
  • Compounds of the invention can be prepared in a variety of ways, some of which are known in the art. In general, the compounds of the present invention can be prepared from commercially available starting materials, compounds known in the literature, or from readily-prepared intermediates, by employing standard synthetic methods and procedures known to those skilled in the art, or which will be apparent to the skilled artisan in light of the teachings herein. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be obtained from the relevant scientific literature or from standard textbooks in the field. Although not limited to any one or several sources, classic texts such as Smith, M. B.; March, J. March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th ed.; John Wiley & Sons: New York, 2001; and Greene, T.W.; Wuts, P.G. M. Protective Groups in Organic Synthesis, 3rd ed.; John Wiley & Sons: New York, 1999, incorporated by reference herein, are useful and recognized reference textbooks of organic synthesis known to those in the art. The following descriptions of synthetic methods are designed to illustrate, but not limit, general procedures for the preparation of compounds of the invention.
  • The compounds of this invention with general formula (I) may be prepared according to the following schemes from commercially available starting materials or starting materials, which can be prepared using literature procedures. These schemes show the preparation of representative compounds of this invention.
    Figure imgb0003
    Figure imgb0004
  • The compounds of formula I of this invention may be prepared by employing reaction as shown in schemes 1 and 2.
  • Compounds encompassed in the invention can be produced according to this or other synthetic processes without departing from the spirit or essential characteristics of the invention. All changes that come within the meaning and range of equivalency of the compounds are intended to be embraced herein. Thus, it is expected that one of ordinary skill in the art would know how to alter the synthetic schemes illustrated herein so as to produce a desired substitution pattern on a compound, produce an increased or decreased product yield, minimize reaction side products, eliminate the use of dangerous or toxic chemical reactants, and/or to produce a desired amount of product (e.g., scale-up reaction size for commercial manufacture), and the like.
  • The present invention further provides a compound prepared by one of the synthetic processes disclosed herein, such as those disclosed in the Examples.
    • 3. Methods of Treatment
  • The present invention also provides compound for use in a method for the treatment of a cell proliferative disorder in a mammal comprising administering to a mammal in need of such treatment, a therapeutically effective amount of a compound of Formula 1. The invention further provides the use of a compound of Formula I for the preparation of a medicament useful for the treatment of a cell proliferative disorder. In one embodiment, the invention provides for the treatment of cancer or precancerous conditions in a mammal comprising administering to a mammal in need of such treatment, a therapeutically effective amount of a compound of Formula I. The mammal can be any mammal, e.g., a human, a primate, mouse, rat, dog, cat, cow, horse, pig. For example, the mammal is a human.
  • An effective amount of a compound of Formula I is used in a method to treat a cell proliferative disorder in a mammal without affecting normal cells of the mammal. For example, a therapeutically effective amount of a compound of Formula I is used in a method for treating cancer in a mammal by inducing cell death in cancer cells without affecting normal cells in the mammal. Cell death can occur by either apoptosis or necrosis mechanisms. In another example, administration of a therapeutically effective amount of a compound of Formula I induces cell death in abnormally proliferating cells without inducing cell death in normal cells.
  • The invention also provides a method of protecting against a cell proliferative disorder in a mammal by administering a therapeutically effective amount of a compound of Formula I to a mammal. The invention also provides the use of a compound of Formula I for the preparation of a medicament useful for the prevention of a cell proliferative disorder. In one embodiment, the invention provides for the prevention of cancer in a mammal comprising administering to a mammal in need of such treatment, a therapeutically effective amount of a compound of Formula I.
  • The compounds of the invention may be administered in the form of pharmaceutical compositions, e.g., as described herein.
  • As used herein, a "subject" can be any mammal, e.g., a human, a primate, mouse, rat, dog, cat, cow, horse, pig, sheep, goat, camel. In a preferred aspect, the subject is a human.
  • As used herein, a "subject in need thereof" is a subject having a cell proliferative disorder, or a subject having an increased risk of developing a cell proliferative disorder relative to the population at large (e.g., a patient that has been diagnosed with a genetic or environmental risk factor). In one aspect, a subject in need thereof has a precancerous condition. In a preferred aspect, a subject in need thereof has cancer.
  • As used herein, the term "cell proliferative disorder" refers to conditions in which the unregulated and/or abnormal growth of cells can lead to the development of an unwanted condition or disease, which can be cancerous or non-cancerous, for example a psoriatic condition. As used herein, the term "psoriatic condition" refers to disorders involving keratinocyte hyperproliferation, inflammatory cell infiltration, and cytokine alteration.
  • In one embodiment, the cell proliferation disorder is cancer. As used herein, the term "cancer" includes solid tumors, such as lung, breast, colon, ovarian, prostate, malignant melanoma, non-melanoma skin cancers, as well as hematologic tumors and/or malignancies, such as childhood leukemia and lymphomas, multiple myeloma, Hodgkin's disease, lymphomas of lymphocytic and cutaneous origin, acute and chronic leukemia such as acute lymphoblastic, acute myelocytic or chronic myelocytic leukemia, plasma cell neoplasm, lymphoid neoplasm and cancers associated with AIDS.
  • In addition to psoriatic conditions, the types of proliferative diseases which may be treated using the compositions of the present invention are epidermic and dermoid cysts, lipomas, adenomas, capillary and cutaneous hemangiomas, lymphangiomas, nevi lesions, teratomas, nephromas, myofibromatosis, osteoplastic tumors, and other dysplastic masses and the like. In one embodiment, proliferative diseases include dysplasias and disorders of the like.
  • As used herein, "monotherapy" refers to administration of a single active or therapeutic compound to a subject in need thereof. Preferably, monotherapy will involve administration of a therapeutically effective amount of an active compound. For example, cancer monotherapy with a compound according to an embodiment of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, to a subject in need of treatment of cancer. Monotherapy may be contrasted with combination therapy, in which a combination of multiple active compounds is administered, preferably with each component of the combination present in a therapeutically effective amount. In one aspect, monotherapy with a compound of the present invention is more effective than combination therapy in inducing a desired biological effect.
  • As used herein, "treating" describes the management and care of a patient for the purpose of combating a disease, condition, or disorder and includes the administration of a compound of the present invention to prevent the onset of the symptoms or complications, alleviating the symptoms or complications, or eliminating the disease, condition or disorder.
  • In one aspect, treating cancer results in a reduction in size of a tumor. In another aspect, treating cancer results in a reduction in tumor volume. In another aspect, treating cancer results in a decrease in number of tumors. In another aspect, treating cancer results in a decrease in number of metastatic lesions in other tissues or organs distant from the primary tumor site. In another aspect, treating cancer results in an increase in average survival time of a population of treated subjects in comparison to a population receiving carrier alone. In another aspect, treating cancer results in an increase in average survival time of a population of treated subjects in comparison to a population of untreated subjects. In another aspect, treating cancer results in increase in average survival time of a population of treated subjects in comparison to a population receiving monotherapy with a drug that is not a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof. In another aspect, treating cancer results in a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving carrier alone. In another aspect, treating cancer results in a decrease in the mortality rate of a population of treated subjects in comparison to an untreated population. In a further aspect, treating cancer results a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving monotherapy with a drug that is not a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof. In another aspect, treating cancer results in a decrease in tumor growth rate. In another aspect, treating cancer results in a decrease in tumor regrowth.
  • In another aspect, treating or preventing a cell proliferative disorder results in a reduction in the rate of cellular proliferation. In another aspect, treating or preventing a cell proliferative disorder results in a reduction in the proportion of proliferating cells. In another aspect, treating or preventing a cell proliferative disorder results in a decrease in size of an area or zone of cellular proliferation. In another aspect, treating or preventing a cell proliferative disorder results in a decrease in the number or proportion of cells having an abnormal appearance or morphology.
  • In additional aspects, a compound of the present invention, or a pharmaceutically acceptable salt, metabolite, analog or derivative thereof, can be administered in combination with a chemotherapeutic agent. Exemplary chemotherapeutics with activity against cell proliferative disorders are known to those of ordinary skill in the art, and may be found in reference texts such as the Physician's Desk Reference, 59th Edition, Thomson PDR (2005). For example, the chemotherapeutic agent can be a taxane, an aromatase inhibitor, an anthracycline, a microtubule targeting drug, a topoisomerase poison drug, a targeted monoclonal or polyclonal antibody, an inhibitor of a molecular target or enzyme (e.g., a kinase inhibitor), or a cytidine analogue drug. In preferred aspects, the chemotherapeutic agent can be, but is not restricted to, tamoxifen, raloxifene, anastrozole, exemestane, letrozole, cisplatin, carboplatin, TAXOL® (paclitaxel), cyclophosphamide, lovastatin, minosine, GEMZAR® (gemcitabine HCl), araC, 5-fluorouracil (5-FU), methotrexate (MTX), TAXOTERE® (docetaxel), ZOLADEX® (goserelin), vincristin, vinblastin, nocodazole, teniposide, etoposide, epothilone, navelbine, camptothecin, daunonibicin, dactinomycin, mitoxantrone, amsacrine, doxorubicin (adriamycin), epirubicin, idarubicin, or GLEEVEC® (imatanib), IRESSA® (gefitinib), TARCEVA® (erlotinib), NEXAVAR® (sorafenib), SUTENT® (sunitinib malate), HERCEPTIN® (trastuzumab), RITUXAN® (Rituximab), ERBITUX® (cetuximab), AVASTIN® (bevacizumab), or agents listed in http://www.cancer.org/docroot/cdg/cdg_0.asp. In another aspect, the chemotherapeutic agent can be a cytokine such as G-CSF (granulocyte colony stimulating factor). In another aspect, a compound of the present invention, or a pharmaceutically acceptable salt, metabolite, analog or derivative thereof may be administered in combination with radiation therapy. In yet another aspect, a compound of the present invention, or a pharmaceutically acceptable salt, metabolite, analog or derivative thereof may be administered in combination with standard chemotherapy combinations such as, but not restricted to, CMF (cyclophosphamide, methotrexate and 5-fluorouracil), CAF (cyclophosphamide, adriamycin and 5-fluorouracil), AC (adriamycin and cyclophosphamide), FEC (5-fluorouracil, epirubicin, and cyclophosphamide), ACT or ATC (adriamycin, cyclophosphamide, and paclitaxel), or CMFP (cyclophosphamide, methotrexate, 5-fluorouracil and prednisone).
    • 4. The Pharmaceutical Compositions and Formulations
  • A "pharmaceutically acceptable salt" or "salt" of the disclosed compound is a product of the disclosed compound that contains an ionic bond, and is typically produced by reacting the disclosed compound with either an acid or a base, suitable for administering to a subject. Pharmaceutically acceptable salt can include, but is not limited to, acid addition salts including hydrochlorides, hydrobromides, phosphates, sulphates, hydrogen sulphates, alkylsulphonates, arylsulphonates, acetates, benzoates, citrates, maleates, fumarates, succinates, lactates, and tartrates; alkali metal cations such as Na, K, Li, alkali earth metal salts such as Mg or Ca, or organic amine salts.
  • A "pharmaceutical composition" is a formulation containing the disclosed compounds in a form suitable for administration to a subject. In one embodiment, the pharmaceutical composition is in bulk or in unit dosage form. The unit dosage form is any of a variety of forms, including, for example, a capsule, an IV bag, a tablet, a single pump on an aerosol inhaler, or a vial. The quantity of active ingredient (e.g., a formulation of the disclosed compound or salts thereof) in a unit dose of composition is an effective amount and is varied according to the particular treatment involved. One skilled in the art will appreciate that it is sometimes necessary to make routine variations to the dosage depending on the age and condition of the patient. The dosage will also depend on the route of administration. A variety of routes are contemplated, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, intranasal, and the like. Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, bioerodable implants and inhalants. In one embodiment, the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that are required.
  • The present invention also provides pharmaceutical formulations comprising a compound of Formula I in combination with at least one pharmaceutically acceptable excipient or carrier. As used herein, "pharmaceutically acceptable excipient" or "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in "Remington: The Science and Practice of Pharmacy, Twentieth Edition," Lippincott Williams & Wilkins, Philadelphia, PA., which is incorporated herein by reference. Examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
  • Methods for formulation are disclosed in PCT International Application PCT/US02/24262 ( WO03/011224 ), U.S. Patent Application Publication No. 2003/0091639 and U.S. Patent Application Publication No. 2004/0071775 , each of which is incorporated by reference herein.
  • A compound of Formula I is administered in a suitable dosage form prepared by combining a therapeutically effective amount (e.g., an efficacious level sufficient to achieve the desired therapeutic effect through inhibition of tumor growth, killing of tumor cells, treatment or prevention of cell proliferative disorders, etc.) of a compound of Formula I (as an active ingredient) with standard pharmaceutical carriers or diluents according to conventional procedures (i.e., by producing a pharmaceutical composition of the invention). These procedures may involve mixing, granulating, and compressing or dissolving the ingredients as appropriate to attain the desired preparation. In another embodiment, a therapeutically effective amount of a compound of Formula I is administered in a suitable dosage form without standard pharmaceutical carriers or diluents.
  • Pharmaceutically acceptable carriers include solid carriers such as lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary liquid carriers include syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may include time-delay material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylate or the like. Other fillers, excipients, flavorants, and other additives such as are known in the art may also be included in a pharmaceutical composition according to this invention.
  • The pharmaceutical compositions containing active compounds of the present invention may be manufactured in a manner that is generally known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes. Pharmaceutical compositions may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and/or auxiliaries which facilitate processing of the active compounds into preparations that can be used pharmaceutically. Of course, the appropriate formulation is dependent upon the route of administration chosen.
  • A compound or pharmaceutical composition of the invention can be administered to a subject in many of the well-known methods currently used for chemotherapeutic treatment. For example, for treatment of cancers, a compound of the invention may be injected directly into tumors, injected into the blood stream or body cavities or taken orally or applied through the skin with patches. For treatment of psoriatic conditions, systemic administration (e.g., oral administration), or topical administration to affected areas of the skin, are preferred routes of administration. The dose chosen should be sufficient to constitute effective treatment but not so high as to cause unacceptable side effects. The state of the disease condition (e.g., cancer, psoriasis, and the like) and the health of the patient should be closely monitored during and for a reasonable period after treatment.
    • EXAMPLES
  • Examples are provided below to further illustrate different features of the present invention. The examples also illustrate useful methodology for practicing the invention. These examples do not limit the claimed invention.
    • Example 1: General procedure A: Synthesis of N-(3-amino-propyl)-3-chloro-N-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-2-fluoro-benzamide (1). General procedure A, Step 1: [(R)-1-(7-Chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-carbamic acid tert-butyl ester
  • Figure imgb0005
  • To a mixture of (R)-2-tert-butoxycarbonylamino-pent-4-ynoic acid (5.0 g, 23.5 mmol) in anhydrous pyridine (20 ml) were added 2-amino-4-chloro-benzoic acid (4.03 g, 23.5 mmol) and triphenyl phosphite (7.40 ml). The reaction mixture was then heated at 55°C for 16 h. To this was added phenylhydrazine (2.8 ml, 28.2 mmol,). The resulting mixture was stirred at 100 °C for 8 h. After the solvent was removed, the residue was purified by flash column (hexane to 20% ethyl acetate in hexane) to give [(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-carbamic acid tert-butyl ester (5.5 g, 53.4%) as off-white solid. M.p.155-157°C. [LC-MS]: 439 [M+H]. 400 MHz 1H NMR: (DMSO-d6) δ 9.21 and 9.0 (s,s, 1H, rotomers), 8.08 (m, 1H), 7.81 (m, 1H), 7.60 (dd, J = 2.0, 6.4 Hz, 1H), 7.31-7.18 (m, 3H), 6.89-6.67 (m, 3H), 5.14-4.97 (m, br, 1H), 2.86 (m, br, 2H), 2.25 (m, I H), 1.32 (s, 9H).
    • Example 2: General procedure A, Step 2: 2-((R)-1-Amino-but-3-ynyl)-7-chloro-3-phenylamino-3H-quinazolin-4-one.
  • Figure imgb0006
  • To a mixture of (R)-[1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-carbamic acid tert-butyl ester (5.35 g, 12.2 mmol) in methanol (65 ml) was added HCl in dioxane (4M, 20 ml). The resulting solution was stirred and the reaction completion was monitored using HPLC/LCMS. The solvent was then removed and the mixture was triturated with diethyl ether to afford 2-((R)-1-amino-but-3-ynyl)-7-chloro-3-phenylamino-3H-quinazolin-4-one (4.60 g, 100%) as off-white solid. M.p. 175-180 °C. LCMS: m/e 339 [M+H]. 1H NMR: (DMSO d6) δ 9.27 (s, 1H), 8.73 (s, br, 3H), 8.15 (d, J = 8.4Hz, 1H), 7.79 (d, J = 2.0Hz, 1 H), 7.70 (dd, J = 2.0 and 8.4Hz, 1H), 7.32 (t, J = 8.0Hz, 2H), 6.92 (t, J = 7.6Hz 1H), 6.68 (m, 2H), 4.90, 4.58 (m, 1H, rotomers), 3.18 (m, 1H), 3.08 (m 2H).
    • Example 3: General procedure A, Step 3: 2-{3-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynylamino]-propyl}-isoindole-1,3-dione.
  • Figure imgb0007
  • To a mixture of (R)-(1-amino-but-3-ynyl)-7-chloro-3-phenylamino-3H-quinazolin-4-one (4.60 g, 12.2 mmol) and diisopropylethylamine (DIPEA) (5.5 ml) in dichloromethane (60 ml) was added a solution of 3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propionaldehyde (2.45 g, 12.1 mmol) in dichloroethane (10 ml), followed by a solution of sodium triacetoxy borohydride (NaBH(OAc)3) (0.25M in dichloroethane, 100 ml). The reaction mixture was stirred at room temperature and the reaction progress was monitored by HPLC/MS. Upon completion, a saturated sodium carbonate solution (100 ml) was added. The resulted organic layer was collected and washed with brine solution. The solvent was removed and residue was purified by flash column to afford 2-{3-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynylamino]-propyl}-isoindole-1,3-dione (6.1 g, 95%) as off-white solid. M.p. 78-80 °C. LCMS: m/e 526 [M+H]. 1H NMR (DMSO-d6): δ 9.0 (s, br, I H), 8.07 (d, J = 8.8 Hz, 1H), 7.74 (m, 1H), 7.83-7.76 (m, 5H), 7.58 (dd, J = 8.8 and 2.0 Hz, 1H), 7.17 (t, J = 7.6 Hz, 2H), 6.83 (brm, 1H), 6.65 (m, 2H), 4.1 and 4.0 (s,s, br, 1H, rotomers), 3.6 (t, J = 6.8Hz, 2H), 2.75 (s, br, 1H), 2.67-2.52 (brm, 2H), 2.35 (brm, 2H), 1.67 (brm, 2H).
    • Example 4: General procedure A, Step 4: 3-Chloro-N-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-N-[3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propyl]-2-fluoro-benzamide.
  • Figure imgb0008
  • To a solution of 3-chloro-2-fluoro-benzoic acid (3.2 g, 18.3 mmol) of in acetonitrile (30 ml) was added 2-chloro-1,3-dimethylimidazolium chloride (DMC) (3.3 g, 19.5 mmol), followed by diisopropylethyl amine (6.8 ml, 39 mmol). The resulted solution was stirred at room temperature for 10 min, then transferred into flask containing (R)-2- {3-[1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynylamino]-propyl; -isoindole-1,3-dione (6.1 g) in a 2.5M solution of diisopropylethyl amine in acetonitrile (30 ml). The reaction mixture was stirred at room temperature and the reaction progress was monitored by HPLC/MS. Upon completion, a saturated solution of sodium carbonate (100 ml) was added. The organic layers were collected and the aqueous layer was washed with EtOAc (2 x 50 ml). The combined organic layers were washed with brine (100 ml) and dried over sodium sulfate. The solvent was removed and residue was separated on silica gel column to afford 3-chloro-N-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-N-[3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)propyl]- 2-fluoro-benzamide as off-white solid (7.6 g, 96%). M.p. 130-132 °C. LCMS: m/e 682 [M+H]. 1H NMR (CDCl3): δ 8.09 (m, 1H), 7.71 (m, 3H), 7.46 (m, 1H), 7.35 (m, 2H), 7.29 (m, 1H), 7.16 (m, 1H), 7.10 (m, 1H), 7.03 (m, 1H), 6.90 (m, 1H), 6.82 (m, 1H), 6.68 (m, 1H), 6.50 (m, 1H), 3.73 (m, 1H), 3.58 (m, 1H), 3.51 (m, 1H), 3.38 (m, 1H), 3.26 (m, 1H), 3.06 (m, 1H), 2.88 (m, 1H), 2.01 (s, 1H), 1.80 (m, 1H), 1.54 (m, 1H).
    • Example 5: General procedure A. Step 5: N-(3-Amino-propyl)-3-chloro-N-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-2-fluoro-benzamide (1).
  • Figure imgb0009
  • To a solution of (R)-3-chloro-N-[1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-N-[3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propyl]-2-fluoro-benzamide (1.13 g, 1.65 mmol) in methanol (10 ml) and the solution was purged with N2. To this solution was added hydrazine (110 µl). The mixture was then stirred at room temperature and the reaction progress was monitored by HPLC/MS. The reaction mixture was then filtered and solvent was removed from the filtrate. The residue was purified by flash column to afford N-(3-amino-propyl)-3-chloro-N-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-2-fluoro-benzamide (708 mg, 91%) as off-white solid, M.p. 101-103 °C. LCMS: m/e 552 [M+H]. 1H NMR (CDCl3): δ 8.13 (d, J = 8.8 Hz, 1H), 7.83 (s, 1H), 7.45 (dd, J = 4.8 and 2.0 Hz, 1H), 7.32 (m, 1H), 7.22 (t, J = 8.0 Hz, 1H), 7.15 (t, J = 8.0 Hz, 1H), 7.05 (t, J = 8.0 Hz, 1H), 6.95 (m, 1H), 6.84 (t, J = 7.2Hz, 1H), 6.72 (d, J = 7.2 Hz, 1H), 6.48 (d, J = 7.2Hz 1H), 3.62 (m, 1H), 3.48 (m, 1H), 3.28 (br, 1H), 3.14 (m, 1H), 3.02 (br, 1H), 2.59 (m, 2H), 2.30 (br, 1H), 2.02 (t, 2.4 Hz, 1H), 1.36 (m, 2H).
    • Example 6: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-4-bromobenzamide (2). (comparative)
  • Figure imgb0010
  • This was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of (R)-2-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-bromo benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 570 [M+H].
    • Example 7: N-(3-Aminopropyl)-N-[1 -(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-4-methylbenzamide (3). (comparative)
  • Figure imgb0011
  • This product was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of (R)-2-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 505 [M+H].
    • Example 8: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-4-chlorobenzamide (4) (comparative)
  • Figure imgb0012
  • This product was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-chloro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 525 [M+H].
    • Example 9: N-(3-Aminopropryl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-4-nitrobenzamide (5). (comparative)
  • Figure imgb0013
  • This product was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-nitro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 536 [M+H].
    • Example 10: N-(3-Aminopropyl)-N-[1 -(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-3,4-dichlorobenzamide (6). (comparative)
  • Figure imgb0014
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 3,4-dichloro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 559 [M+H].
    • Example 11: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-2,3-difluorobenzamide (7). (comparative)
  • Figure imgb0015
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 2,3-difluoro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 527 [M+H].
    • Example 12: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-4-fluorobenzamide (8). (comparative)
  • Figure imgb0016
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-fluoro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 509 [M+H].
    • Example 13: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-3,4-difluorobenzamide (9).(comparative)
  • Figure imgb0017
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 3,4-difluoro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 527 [M+H].
    • Example 14: N-(3-Aminopropyl-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-2,3,4-trifluorobenzamide (10). (comparative)
  • Figure imgb0018
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 2,3,4-trifluoro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 545 [M+H].
    • Example 15: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-3,5-dichlorobenzamide (11). (comparative)
  • Figure imgb0019
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 3,5-dichloro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/c 560 [M+H].
    • Example 16: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-2,3-dichlorobenzamide (12). (comparative)
  • Figure imgb0020
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 2,3-dichloro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 560 [M+H].
    • Example 17: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-3-chloro-4-fluorobenzamide (13). (comparative)
  • Figure imgb0021
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 3-chloro-4-fluoro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 543 [M+H].
    • Example 18: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-3-bromobenzamide (4). (comparative)
  • Figure imgb0022
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 3-bromo benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 570 [M+H].
    • Example 19: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-4-iodobenzamide (15). (comparative)
  • Figure imgb0023
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-iodo benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 617 [M+H].
    • Example 20: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-3-fluoro-4-methylbenzamide (16). (comparative)
  • Figure imgb0024
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 3-fluoro-4-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 523 [M+H].
    • Example 21: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-2.6-difluoro-3-methylbenzamide (17). (comparative)
  • Figure imgb0025
  • This compound was synthesized as described in "general procedure A," except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 2,6-difluoro-3-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 541 [M+H].
    • Example 22: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-4-fluoro-3-methylbenzamide (18). (comparative)
  • Figure imgb0026
  • This compound was synthesized as described in "general procedure A," except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-fluoro-3-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 523 [M+H].
    • Example 23: N-(3-Aminopropyl)-N-[1 -(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-3-chloro-2-fluorobenzamide (19). (comparative)
  • Figure imgb0027
  • This compound was synthesized as described in "general procedure A," except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid as described in general procedure A. LCMS: m/e 543 [M+H].
    • Example 24: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-3-chloro-2,4-difluorobenzamide (20), (Comparative)
  • Figure imgb0028
  • This compound was synthesized as described in "general procedure A," except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 3-chloro-2,4-difluoro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 561 [M+H].
    • Example 25: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-2,3-difluoro-4-methylbenzamide(21), (comparative)
  • Figure imgb0029
  • This compound was synthesized as described in "general procedure A," except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 2,3-difluoro-4-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 541 [M+H].
    • Example 26: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3.4-dihydroquinazolin-2-yl)propyl]quinoline-2-carboxamide (22). (Comparative)
  • Figure imgb0030
  • This compound was synthesized as described in "general procedure A," except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and quinoline-2-carboxylic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 542 [M+H].
    • Example 27: N-(3-Aminooropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-4-(1H-pyrazol-1-yl)benzamide(23). (Comparative)
  • Figure imgb0031
  • This compound was synthesized as described in "general procedure A," except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-pyrazole-yl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 557 [M+H].
    • Example 28: N-(3-Aminopropyl)-N-(1-{7-chloro-3-[(3-fluorophenyl)amino]-4-oxo-3,4-dihydroquinazolin-2-yl}propyl)-4-methylbenzamide (24). (Comparative)
  • Figure imgb0032
  • This compound was synthesized as described in "general procedure A," except 3-fluoro phenyl hydrazine was used instead of phenyl hydrazine, N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 523 [M+H].
    • Example 29: N-(3-Aminopropyl)-N-(1-{7-chloro-3-[(2-fluorophenyl)amino]-4-oxo-3,4-dihydroquinazolin-2-yl}propyl)-4-methylbenzamide(25). (Comparative)
  • Figure imgb0033
  • This compound was synthesized as described in "general procedure A," except 2-fluoro phenyl hydrazine was used instead of phenyl hydrazine, N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 523 [M+H].
    • Example 30: N-(3-Aminoproyl)-N-(1-{7-chloro-3-[(2,5-difluorophenyl)amino]-4-oxo-3,4-dihydroquinazolin-2-yl}propyl)-4-methylbenzamide (26), (Comparative)
  • Figure imgb0034
  • This compound was synthesized as described in "general procedure A," except 2, 5-difluoro phenyl hydrazine was used instead of phenyl hydrazine, N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 541 [M+H].
    • Example 31:N-(3-Aminopropyl)-N-[1-(3-anilino-6-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-4-methylbenzamide (27). (Comparative)
  • Figure imgb0035
  • This compound was synthesized by using 2-amino-5-chloro benzoic acid instead of 2-amino-4-chloro benzoic acid as described in "general procedure A," and, N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 505 [M+H].
    • Example 32: N-(3-Aminopropyl)-N-[1-(3-anilino-6-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-4-methylbenzamide (28). (Comparative)
  • Figure imgb0036
  • This compound was synthesized by using 2-amino-5-methyl benzoic acid instead of 2-amino-4-chloro benzoic acid as described in "general procedure A," and N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 484 [M+H].
    • Example 33: N-(3-Aminopropyl)-N-[1-(7-chloro-4-oxo-3-phenoxy-3,4-dihydroquinazolin-2-yl)propyl]-4-methylbenzamide(29). (Comparative)
  • Figure imgb0037
  • This compound was synthesized by using O-phenyl hydroxylamine instead of phenyl hydrazine in procedure as described in "general procedure A,", N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 506 [M+H].
    • Example 34: General Procedure B
  • Sulfonylation of 2- {3-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynylamino]-propyl}-isoindole-1,3-dione followed by deprotection.
    Figure imgb0038
    • Example 35: Synthesis of N-(3-amino-propyl)-N-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-4-methyl-benzenesulfonamide(30).
  • Figure imgb0039
  • A solution of 2- {3-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynylamino]-propyl}-isoindole-1,3-dione (52.6 mg, 0.10 µmol) in pyridine (0.5 mL) was treated with respective sulfonyl chloride (in this case 4-methyl benzenesulfonyl chloride, 0.25M solution in DMA/AcCN (1:1), 0.5 mL, 0.125 µmol,). The mixture was stirred at 45 °C for 24 h. Solvent was removed under reduced pressure. Residue was taken in MeOH (1.0 mL) and treated with hydrazine (0.25 mL). Reaction mixture was stirred at room temperature for 16h and solvent removed under reduced pressure. The product was purified with reverse phase chromatography to give final product. Yield (10.4 mg, 20%). LCMS: m/e 551 [M+H].
    • Example 36: N-(3-Aminopropyl)-N-[(1R)-1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-3-fluorobenzenesulfonamide(31). (Comparative)
  • Figure imgb0040
  • This compound was synthesized as described in "general procedure A," except N-Boc-D-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 3-fluoro benzenesulfonyl chloride was used as described in general procedure B. LCMS: m/e 545 [M+H].
    • Example 37: N-(3-Aminopropyl)-N-{1-[3-(benzyloxy)-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl]propyl}-4-methylbenzamide (32). (Comparative)
  • Figure imgb0041
  • This compound was synthesized by using O-benzyl hydroxyl amine instead of phenyl hydrazine as described in "general procedure A," except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 520 [M+H].
    • Example 38: N-(3-Aminopropyl)-N-[(1R)-1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-1,3,5-trimethyl-1H-pyrazole-4-sulfonamide(33). (Comparative)
  • Figure imgb0042
  • This compound was synthesized as described in "general procedure A," except N-Boc-D-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 1,3,5-trimethyl-1H-pyrazole-4-sulfonyl chloride was used as described in general procedure B. LCMS: m/e 559 [M+H].
    • Example 39: N-(3-Aminopropyl)-N-[(1R)-1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]thiophene-3-sulfonamide (34). (Comparative)
  • Figure imgb0043
  • This compound was synthesized as described in "general procedure A," except N-Boc-D-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and thiophene-3-sulfonyl chloride was as described in general procedure B. LCMS: m/e 533 [M+H].
    • Example 40: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-3-methylbutyl]-3,4-difluorobenzamide (35). (Comparative)
  • Figure imgb0044
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-leucine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 3,4-difluoro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 555 [M+H].
    • Example 41: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-3-methylbutyl]-3,5-dichlorobenzamide (36). (Comparative)
  • Figure imgb0045
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-leucine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 3,5-dichloro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 588 [M+H].
    • Example 42: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-3-methylbutyl]-3-chloro-4-fluorobenzamide (37). (Comparative)
  • Figure imgb0046
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-leucine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 3-chloro-4-fluoro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 571 [M+H].
    • Example 43: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-3-(methythiol)propyl]-3-chloro-2-fluorobenzamide (38). (Comparative)
  • Figure imgb0047
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-methionine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid as described in general procedure A. LCMS: m/e 589 [M+H].
    • Example 44: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3.4-dihydroquinazolin-2-yl)-3-(methylthio)propyl]-2,3-difluoro-4-methylbenzamide (39). (Comparative)
  • Figure imgb0048
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-methionine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 2,3-difluoro-4-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 587 [M+H].
    • Example 45: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-3-(methylthio)propyl]l-4-(1H-pyrazol-1-yl)benzamide (40). (Comparative)
  • Figure imgb0049
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-methionine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-pyrazol-1-yl-benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 603 [M+H].
    • Example 46: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl]-3,4-dichlorobenzamide (41). (Comparative)
  • Figure imgb0050
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-alanine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 3, 4-dichlorobenzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 546 [M+H].
    • Example 47: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-2,3-difluorobenzamide (42). (Comparative)
  • Figure imgb0051
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-valine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 2,3-difluorobenzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 541 [M+H].
    • Example 48: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-fluorobenzamide(43). (Comparative)
  • Figure imgb0052
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-valine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-fluoro-benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 523 [M+H].
    • Example 49: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-3-bromobenzamide (44). (Comparative)
  • Figure imgb0053
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-valine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 3-bromo-benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 584 [M+H].
    • Example 50: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-chloro-2,5-difluorobenzamide (45). (Comparative)
  • Figure imgb0054
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-valine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 2,5-difluoro-4-chloro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 575 [M+H].
    • Example 51: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-3-fluoro-4-methylbenzamide (46). (Comparative)
  • Figure imgb0055
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-valine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 3-fluoro-4-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 537 [M+H].
    • Example 52: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyllquinoline-2-carboxamide (47). (Comparative)
  • Figure imgb0056
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-valine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and quinoline-2-carboxylic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 556 [M+H].
    • Example 53: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-(2-thienyl)ethyl]-4-bromobenzamide (48). (Comparative)
  • Figure imgb0057
  • This compound was synthesized as described in general procedure A, except N-Boc-beta-(2-thienyl)-DL-alanine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-bromo benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 638 [M+H].
    • Example 54: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-(2-thienyl)ethyl]-4-methylbenzamide(49). (Comparative)
  • Figure imgb0058
  • This compound was synthesized as described in general procedure A, except N-Boc-beta-(2-thienyl)-DL-alanine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 573 [M+H].
    • Example 55: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3.4-dihyquinazolin-2-yl)-2-(2-thienyl)ethyl]-2,3-difluorobenzamide(50). (Comparative)
  • Figure imgb0059
  • This compound was synthesized as described in general procedure A, except N-Boc-beta-(2-thienyl)-DL-alanine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 2,3-difluoro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 595 [M+H].
    • Example 56: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-(2-thienyl)ethyl]-4-fluorobenzamide (51). (Comparative)
  • Figure imgb0060
  • This compound was synthesized as described in general procedure A, except N-Boc-beta-(2-thienyl)-DL-alanine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-fluoro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 577 [M+H].
    • Example 57: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-(2-thienyl)ethyl]-3,4-difluorobenzamide (52). (Comparative)
  • Figure imgb0061
  • This compound was synthesized as described in general procedure A, except N-Boc-beta-(2-thienyl)-DL-alanine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 3,4-difluoro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 595 [M+H].
    • Example 58: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-(2-thienyl)ethyl]-3-chloro-4-fluorobenzamide (53). (Comparative)
  • Figure imgb0062
  • This compound was synthesized as described in general procedure A, except N-Boc-beta-(2-thienyl)-DL-alanine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 3-chloro-4-fluoro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A LCMS: m/e 611 [M+H]
    • Example 59: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-(4-hydroxyphenyl)ethyl]-3,4-dichlorobenzamide (54). (Comparative)
  • Figure imgb0063
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-tyrosine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 3,4-dichloro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 638 [M+H].
    • Example 60: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3.4-dihydroquinazolin-2-yl)-2-(4-hydroxyphenyl)ethyl]-2,3,4-trifluorobenzamide(55). (Comparative)
  • Figure imgb0064
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-tyrosine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 2,3,4-trifluoro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 623 [M+H].
    • Example 61: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)but-3-yn-1-yl]-4-chloro-2,5-difluorobenzamide (56).
  • Figure imgb0065
  • This compound was synthesized as described in general procedure A, except DL-tert-butoxycarbonylamino-pent-4-ynoic acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 2,5,-difluoro-4-chloro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 571 [M+H].
    • Example 62: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)but-3-yn-1-yl]-3-chloro-2-fluorobenzamide (57).
  • Figure imgb0066
  • This compound was synthesized as described in general procedure A, except DL-tert-butoxycarbonylamino-pent-4-ynoic acid was used as described in general procedure A. LCMS: m/e 553 [M+H].
    • Example 63: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-3,3-dimethylbutyl]-4-bromobenzamide (58). (Comparative)
  • Figure imgb0067
  • This compound was synthesized as described in general procedure A, except beta-tert butyl-N-Boc-DL-alanine was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-bromo benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 612 [M+H].
    • Example 64: N-(3-Aminopropyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)pentyl]-4-methylbenzamide (59). (Comparative)
  • Figure imgb0068
  • This compound was synthesized as described in general procedure A, except 2-amino hexanoic acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid and 4-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 533 [M+H].
    • Example 65: N-(2-Aminoethyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-4-chlorobenzamide (60). (Comparative)
  • Figure imgb0069
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid, (1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetaldehyde was used instead of 3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propionaldehyde and 4-chloro benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 511 [M+H].
    • Example 66: N-(2-Aminoethyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-4-methylbenzamide (61). (Comparative)
  • Figure imgb0070
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid, (1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetaldehyde was used instead of 3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propionaldehyde and 4-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A LCMS: m/e 491 [M+H].
    • Example 67: N-(2-Aminoethyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-2,6-difluoro-3-methylbenzamide (62). (Comparative)
  • Figure imgb0071
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid, (1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetaldehyde was used instead of 3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propionaldehyde and 2,6-difluoro-3-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 527 [M+H].
    • Example 68: N-(2-Aminoethyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-4-fluoro-3-methylbenzamide (63). (Comparative)
  • Figure imgb0072
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid, (1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetaldehyde was used instead of 3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propionaldehyde and 4-fluoro-3-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 509 [M+H].
    • Example 69: N-(2-Aminoethyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-3-chloro-2-fluorobenzamide (64). (Comparative)
  • Figure imgb0073
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid, (1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetaldehyde was used instead of 3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propionaldehyde as described in general procedure A. LCMS: m/e 529 [M+H].
    • Example 70: N-(2-Aminoethyl)-N-[1-(3-anilino-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-2,3-difluoro-4-methylbenzamide (65). (Comparative)
  • Figure imgb0074
  • This compound was synthesized as described in general procedure A, except N-Boc-DL-2-amino butyric acid was used instead of (R)-tert-butoxycarbonylamino-pent-4-ynoic acid, (1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetaldehyde was used instead of 3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propionaldehyde and 2,3-difluoro-4-methyl benzoic acid was used instead of 2-fluoro-3-chloro benzoic acid as described in general procedure A. LCMS: m/e 527 [M+H].
    • Example 71: General Procedure C
  • Reductive amination of 2-{3-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynylamino]-propyl}-isoindole-1,3-dione followed by deprotection.
    Figure imgb0075
    • Example 72: 2-{(R)-1-[(3-Amino-propyl)-(4-methyl-benzyl)-amino]-but-3-ynyl}-7-chloro-3-phenylamino-3H-quinazolin-4-one (66).
  • Figure imgb0076
  • A solution of 2- {3-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynylamino]-propyl}-isoindole-1,3-dione (52.6 mg, 0.10 µmol) in dichloroethane (0.5 mL) was treated with respective aldehydes (in this case 4-methyl benzaldehyde, 0.25M solution in DCE, 0.8 mL, 0.2 µmol,). The mixture was stirred at room temperature for 16 h. Solvent was removed under reduced pressure. Residue was taken in MeOH(1.0 mL) and treated with hydrazine (0.25 mL). Reaction mixture was stirred at room temperature for 16h and solvent removed under reduced pressure. The product was purified with reverse phase chromatography to give final product. Yield (14mg, 24%). LCMS: m/e 500 [M+H].
    • Example 73: 2-{1-[(3-Aminopropyl)(4-methyl-benzyl)amino]propyl}-3-anilino-7-chloro-3H-quinazolin-4-one (67). (Comparative)
  • Figure imgb0077
  • This compound was synthesized as described in general procedure C except 2-{3-[1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-propylamino]-propyl}-isoindole-1,3-dione was used instead of (R)-2-(3-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynylamino)propyl)isoindoline-1,3-dione. LCMS: m/e 491 [M+H].
    • Example 74: 2-{(R)-1-[(3-Amino-propyl)-(4-methyl-benzyl)-amino]-propyl}-7-chloro-3-phenylamino-3H-quinazolin-4-one (68). (Comparative)
  • Figure imgb0078
  • This compound was synthesized as described in general procedure C except 2-{3-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-propylamino]-propyl} -isoindole-1,3-dione was used instead of (R)-2-(3-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynylamino)propyl)isoindoline-1,3-dione. LCMS: m/e 491 [M+H].
    • Example 75: 2-{(1R)-1-[(3-Aminopropyl)(4-fluoro-3-methylbenzyl)amino]propyl}-3-anilino-7-chloro-3H-quinazolin-4-one (69). (Comparative)
  • Figure imgb0079
  • This compound was synthesized as described in general procedure C except 2-{3-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-propylamino]-propyl} -isoindole-1,3-dione was used instead of (R)-2-(3-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynylamino)propyl)isoindoline-1,3-dione and 4-flouro-3-methyl benzaldehyde was used instead of 4-methyl benzaldehyde. LCMS: m/e 508.04 [M+H].
    • Example 76: 2{(1R)-1-[(3-aminopropyl)(benzyl)amino]propyl}-3-anilino-7-chloro-3H-quinazolin-4-one (70). (Comparative)
  • Figure imgb0080
  • This compound was synthesized as described in general procedure C except 2-{3-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-propylamino]-propyl} -isoindole-1,3-dione was used instead of (R)-2-(3-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynylamino)propyl)isoindoline-1,3-dione and benzaldehyde was used instead of 4-methyl benzaldehyde. Yield (16 %). LCMS: m/e 477.04 [M+H].
    • Example 77: General Proedure D; Synthesis of (R)-N-(3-aminopropyl)-3-chloro-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2-fluorobenzamide (1).
  • Figure imgb0081
    • Example 78: (R)-benzyl 3-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynylamino)propyl carbamate.
  • Figure imgb0082
  • (R)-2-(1-Aminobut-3-ynyl)-7-chloro-3-(phenylamino)quinazolin-4(3H)-one (185mg, 0.54 mmol) was dissolved in 1,2-dichloroethane (10 mL) and N,N,-diisopropylethylamine (1.62 mmol) was added and stirred for 5 min where upon of 3-N-carbonyloxybenzyl propanaldehyde (0.59 mmol) and sodiumtriacetocyborohydride (1.18 mmol) were added and reaction was allowed to stir for 18 hours as LCMS showed presence of starting material after few hours. Upon completion, the reaction was quenched with sodium carbonate solution and extracted with 100 mL of dichloromethane and the organic layer was dried over sodium sulfate. Removal of solvent under reduced pressure gave (R)-benzyl 3-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynylamino)propylcarbamate (>90%). M.p. = 63-65 °C; 400 MHz 1H NMR (DMSO-d6) δ: 9.09 (s, 1H), 8.07 (d, J= 8.8, 1H), 7.83 (s, br, 1H), 7.59-7.56 (dd, J= 2.0; 6.4, 1H), 7.29 (m, 5H), 7.18 (m, 2H), 6.83 (t, J= 7.6. 1H), 6.67 (d, J= 8.0, 2H), 4.95 (s, 2H), 4.20 (s, br,1H), 4.00, s, br, 1H), 3.03-2.98 (dd, 2H), 2.75-2.5 (m, 3H), 2.3 (m, br 2H), 1.46 (m, 2H); LCMS: 530 [M+H].
    • Example 79: (R)-Benzyl 3-(3-chloro-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2-fluorobenzamido)propyl carbamate.
  • Figure imgb0083
  • (R)-Benzyl 3-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynylamino)propylcarbamate(0.28 g, 0.53 mmol) was dissolved in dichloromethane (5 mL). Triethylamine (0.22 mL, 1.60 mmol) was added followed by the addition of 2-fluoro-3-chlorobenzoyl chloride (0.112 g, 0.58 mmol). The reaction was stirred under a nitrogen atmosphere until the reaction was complete (LC/MS) (total of 5 min). The mixture was stirred for an additional 10 min, diluted with dichloromethane (50 mL) and washed with aqueous sodium bicarbonate (5 mL), water (5 ml X 2) and brine solution and dried over anhydrous sodium sulfate. The solid was removed by filtration and the solvent removed under vacuum to provide (R)-benzyl 3-(3-chloro-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2-fluorobenzamido)propyl-carbamate as an orange solid (0.31 g, 0.45 mmol, 84%). mp 103-105°C. 1H-NMR (DMSO-d6 ): δ 9.41-8.94 (m, 1H), 8.21-5.62 (m, 16H), 5.35-4.80 (m, 2H), 3.46-1.15 (m, 11H). LC/MS: 686 [M+H].
    • Example 80: (R)-N-(3-Aminopropyl)-3-chloro-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2-fluorobenzamide (1).
  • Figure imgb0084
  • (R)-Benzyl 3-(3-chloro-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2-fluorobenzamido) propyl carbamate (0.62 g, 0.90 mmol), 1-ethynylcyclohexene (0.478 mL, 4.50 mmol) in ACN (20 mL) was added iodo-trimethylsilane (1.3 mL, 9.0 mmol). The reaction mixture was stirred at room temperature for 3 h. The resulting mixture was quenched with 10% aq Na2CO3 (40 mL). The layers were separated and the aqueous layer was washed with DCM (2 x 30 mL). The combined organic layers were washed with brine (1 x 40 mL), dried over MgSO4, filtered and concentrated to yield an orange solid (1.2 g). The residue was separated on silica gel column (25%-50% EtOAc/Hex) to provide (R)-N-(3-aminopropyl)-3-chloro-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2-fluorobenzamide (0.24 g, 48%); mp 175°C. 1H-NMR (DMSO-d6 ): δ 9.39-8.94 (m, 1H), 8.18-5.90 (m, 11H), 5.00-4.74 (m, 1H), 4.00-0.85 (m, 11H). LC/MS: 552 [M+H].
    • Example 81: N-(3-Amino-pronyl)-N-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydroquinazolin-2-yl-but-3-ynyl)-2,3,5,6-tetrafluoro-benzamide (71).
  • Figure imgb0085
  • This compound was synthesized as described in general procedure D, except 1,2,4,5 tetrafluoro benzoyl chloride was used instead of 2-fluoro-3-chloro benzoyl chloride. M.p. 156-158 °C. LCMS: m/e 572 [M+H]. 1H NMR (CDCl3): δ 9.21-9.0 (m, 1H), 8.18-7.52 (m, 4H), 7.31-7.05 (m, 2H), 6.97-6.63 (m, 2H), 6.58-6.22 (m, I H), 5.02-4.83 (m, I H), 4.05-3.88 (m, I H), 3.81-2.84 (m, 4H), 2.93-2.60 (m, 1H), 2.56-1.37 (m, 5H).
    • Example 82: (R)-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,3,4,5-tetrafluorobenzamide (72).
  • Figure imgb0086
  • This compound was synthesized as described in general procedure D, except 2,3,4,5 tetrafluoro benzoyl chloride was used instead of 2-fluoro-3-chloro benzoyl chloride, M.p. = 155-158 °C; 400 MHz 1H NMR (DMSO-d6) δ: 9.4-4.8 (m,12H), 4.0-0.8 (m, 10H); LCMS: 572 [M+H].
    • Example 83: (R)-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)benzo[b]thiophene-2-carboxamide (73).
  • Figure imgb0087
  • This compound was synthesized as described in general procedure D, except benzo[b]thiophene-2-carbonyl chloride was used instead of 2-fluoro-3-chloro benzoyl chloride, M.p. = 103-106 °C; 400 MHz 1H NMR (DMSO-d6) δ: 9.3-5.7 (m,16H), 4.1-0.7 (m, 10H); LCMS: 556 [M+H].
    • Example 84: N-(3-Aminopropyl)-3-chloro-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)pent-3-ynyl)-2-fluorobenzamide (74).
  • Figure imgb0088
  • This compound was synthesized as described in general procedure D, except (DL)-2-tert-butoxycarbonylamino-hex-4-ynoic acid was used instead of (R)-2-tert-butoxycarbonylaminopent-4-ynoic acid M.p. = 185-190 °C; 1 H NMR 400 MHz (DMSO-d6) δ: 9.4-4.9 (m, 14H), 4.1-1.0 (m, 12H); LCMS: 566 [M+H].
    • Example 85: N-(3-Amino-propyl)-N-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-4-methyl-benzamide (75).
  • Figure imgb0089
  • This compound was synthesized as described in general procedure D, except 4-methyl benzoyl chloride was used instead of 2-fluoro-3-chloro benzoyl chloride. M.p. = 130-133 °C (Dec.); 400 MHz 1H NMR (DMSO-d6) δ: 9.2-6.3 (m,15H), 4.0-0.8 (m, 13H); LCMS: 514 [M+H].
    • Example 86: N-(3-Amino-propyl)-N-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-2,3-difluoro-4-methyl-benzamide (76).
  • Figure imgb0090
  • This compound was synthesized as described in general procedure D, except 2,3-difluoro-4-methyl benzoyl chloride was used instead of 2-fluoro-3-chloro benzoyl chloride. M.p. = 175-180 °C; 400 MHz 1H NMR (DMSO-d6) δ: 9.7-6.2 (m,13H), 4.9-1.2 (m, 13H); LCMS: 550 [M+H].
    • Example 87: (R)-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,3-difluoro-6-methoxybenzamide (77).
  • Figure imgb0091
  • This compound was synthesized as described in general procedure D, except 2,3,-di-fluoro-6-methoxy benzoyl chloride was used instead of 2-fluoro-3-chloro benzoyl chloride. M.p. 138-145 °C. 1H NMR 400 MHz (DMSO): δ 9.17-8.9 (m, 1H), 8.07 (s, 1H), 7.94-7.68 (m, 1H), 7.65-7.50 (m, 4H), 7.19-7.04 (m, 3H), 6.87-6.79 (m, 2H), 6.69-6.51 (m, 3H), 6.24-6.18 (m, 1H), 4.89 (d, J=10.56Hz 1H), 3.87-3.74 (m, 2H), 3.64-3.36 (m, 2H), 3.19-2.88 (m, 2H), 2.69-2.53 (m, 2H), 1.65-1.55 (m, 1H). LCMS: m/e 566 [M+H].
    • Example 88: (R)-N-(3-Aminonronyl)-N-(1-(7-chloro-4-oxo-3-phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,3-difluoro-4-methoxybenzamide (78).
  • Figure imgb0092
  • This compound was synthesized as described in general procedure D, except 2,3,-di-fluoro-4-methoxy benzoyl chloride was used instead of 2-fluoro-3-chloro benzoyl chloride. M.p. 135-140 °C. 1H NMR (DMSO): δ 9.12-9.00 (m, 1H), 8.14-6.48 (m, 13H), 5.28 (br, 1H), 3.91-3.86 (m, 1H), 3.81-3.73 (m, 2H), 3.46-3.30 (m, 2H), 3.28-3.06 (m, 1H), 2.96-2.89 (m, 1H), 2.73-2.65 (m, 1H), 2.45-2.56 (m, 1H), 2.31-2.13 (m, 1H), 2.06 (s, 1H). LCMS: m/e 566.17 [M+H].
    • Example 89: (R)-N-(3-Aminopropyl)-4-chloro-N-(1-(7-chloro-4-oxo-3-phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,6-difluoro-benzamide (79).
  • Figure imgb0093
  • This compound was synthesized as described in general procedure D, except 2,6,-di-fluoro-4-chloro benzoyl chloride was used instead of 2-fluoro-3-chloro benzoyl chloride. M.p. 140-145 °C. 1H NMR (DMSO): δ 9.09-9.05 (m, 1H), 8.11-07 (m, 1H), 7.92-7.89 (m, 1H), 7.85-7.73 (m, 1H), 7.68-7.52 (m, 4H), 7.35-7.17 (m, 2H), 7.15-7.04 (m, 3H), 6.86-6.81 (m, 2H), 6.56-6.54 (d, J=8,22 Hz, 1H), 6.28-6.26(d, J=8.22Hz, 1H), 4.98-4.96 (m, 1H), 3.94-3.62(m, 2H), 3.16-2.93 (m, 4H), 2.77-2.65(m, 2H). LCMS: m/e 571 [M+H].
    • Example 90: (R)-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-3,5-difluorobenzamide (80).
  • Figure imgb0094
  • This compound was synthesized as described in general procedure D, except 3,5,-di-fluoro benzoyl chloride was used instead of 2-fluoro-3-chloro benzoyl chloride, M.p. 165-167 °C. LCMS: m/e 536 [M+H]. 1H NMR (DMSO-d6): δ 9.18 (s. 1H), 8.12 (m, 1H), 7.95 (s, 1H), 7.65 (m, 3H), 7.38 (d, J = 8.0 Hz, 2H), 7.04 (m, 2H), 6.79 (m, 1H), 6.46 (d, J = 7.6 Hz, 1H), 4.97 (m, 1H), 3.18 (m, 2H), 3.01 (m, 2H), 2.73 (m, 2H), 1.91 (s, 1H), 1.73 (m, 2H), 1.33-1.19 (m, 2H).
    • Example 91: (R)-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,3,5-trifluorobenzamide (81).
  • Figure imgb0095
  • This compound was synthesized as described in general procedure D, except 2,3,5,-tri-fluoro benzoyl chloride was used instead of 2-fluoro-3-chloro benzoyl chloride, m.p. 168-170°C. LC-MS: m/e 554 [M+H]. 1H NMR (CDCl3): δ 8.14 (s, 1H), 8.06 (t, J=6.8Hz, 1H), 7.81 (m, 1H), 7.41 (m, 1H), 7.06 (m, 2H), 6.81-6.88 (m, 2H), 6.62-6.72 (m, 3H), 5.04 (t, J=13.2Hz), 3.79 (m, 1H), 3.63-3.81 (m, 2H), 3.52 (m, 1H), 3.15 (q, J=7.2Hz, 1H), 2.97 (br s, 2H), 2.63-2.69 (m, 1H), 2.06 (d, J=6.8Hz, 1H), 1.95 (m, 1H), 1.44 (t, J=7.2Hz, 1H), 1.26 (m, 1H).
    • Example 92: (R)-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,3-difluorobenzamide (82).
  • Figure imgb0096
  • This compound was synthesized as described in general procedure D, except 2,3,-di-fluoro benzoyl chloride was used instead of 2-fluoro-3-chloro benzoyl chloride, m.p. 168-170 °C. LC-MS: m/e 536 [M+H]. 1H NMR (CDCl3): δ 8.14 (s, 1H), 8.06 (t, J=6.8Hz, 1H), 7.81 (m, 1H), 7.41 (m, 1H), 7.06 (m, 2H), 6.81-6.88 (m, 2H), 6.62-6.72 (m, 3H), 5.04 (t, J=13.2Hz), 3.79 (m, 1H), 3.63-3.81 (m, 2H), 3.52 (m, 1H), 3.15 (q, J=7.2Hz, 1H), 2.97 (br s, 2H), 2.63-2.69 (m, 1H), 2.06 (d, J=6.8Hz, 1H), 1.95 (m, 1H), 1.44 (t, J=7.2Hz, 1H), 1.26 (m, 1H).
    • Example 93: General procedure E: Synthesis of (R)-N-(3-aminopropyl)-3-chloro-2-fluoro-N-(1-(4-oxo-3-(phenylamino)-3,4-dihydropyrido[3,2-d]pyrimidin-2-yl)but-3-ynyl)benzamide (83).
  • Figure imgb0097
    • Example 94: (R)-tert-butyl 1-(4-oxo-3-(phenylamino)-3,4-dihydropyrido[3,2-d]pyrimidin-2-yl)but-3-ynylcarbamate.
  • Figure imgb0098
  • To a mixture of 3-aminopicolinic acid (1.94 g, 14.06 mmol) and D-boc-propargylglycine in pyridine (anhydrous, 50 ml) was added triphenylphosphite (4.43 ml, 16.87 mmol). The mixture was heated at 55 °C for 18 hours. After cooling to room temperature, phenyl hydrazine (1.66 ml, 16.87 mmol) was added. The resulted mixture was stirred at 110 °C for four days. The solvent was removed under reduced pressure. 250 ml of EtOAc and 80 ml of water were added to the residue. The organic layer was separated, then washed with brine (80 ml), dried over Na2SO4 and concentrated to dryness under reduced pressure. The crude produce was purified by flash silica gel chromatography eluting with hexanes/EtOAc(1:1) to afford (R)-tert-butyl 1-(4-oxo-3-(phenylamino)-3,4-dihydropyrido[3,2-d]pyrimidin-2-yl)but-3-ynylcarbamate (2.12 g, 37 %) as a light brown solid, M.p. 108-110 °C. LCMS: m/e 406 [M+H]. 1H NMR, 400MHz (CDCl3): δ 8.87 (d, J = 4 Hz, 1H), 8.15 (d, J = 8.0 Hz, I H), 7.73 (m, I H), 7.24 (m, 3H), 7.00 (t, J = 8.0 Hz, I H), 6.78 (s, 2H), 5.88 (m, 1H), 5.32 (s, 1H), 3.10-2.62 (m, 2H), 1.96 (s, 1H), 1.45 (s, 9H).
    • Example 95: (R)-2-(1-Aminobut-3-ynyl)-3-(phenylamino)pyrido[3,2-d]pyrimidin-4(3H)-one.
  • Figure imgb0099
  • To a solution of (R)-tert-butyl 1-(4-oxo-3-(phenylamino)-3,4-dihydropyrido[3,2-d]pyrimidin-2-yl)but-3-ynylcarbamate (1.20 g, 2.96 mmol) in methanol (15 ml) was added 4.5 ml of HCl (4.0 M in 1,4-dioxane). The reaction was carried out at room temperature for 18 hours. The solvent was removed under reduced pressure to afford (R)-2-(1-aminobut-3-ynyl)-3-(phenylamino)pyrido[3,2-d]pyrimidin-4(3H)-one (1.1 g) as a light brown solid, M.p. 206-208 °C. LCMS: m/e 306 [M+H]. 1H NMR (400MHz) (DMSO-d6): δ 9.3 (s, 1H), 8.85 (s, 1H), 8.20 (d, J = 8 Hz, 1H), 7.94 (dd, J = 8.0 Hz and 3.2 Hz, 1H), 7.22 (t, J = 7.6 Hz, 2H), 6.91 (t, J = 7.6 Hz, 1H), 6.80 (s, J = 8 Hz, 1H), 4.98 (m, 3H), 4.53 (s, 1H), 3.11 (m, 2H).
    • Example 96: (R)-Benzyl 3-(1-(4-oxo-3-(phenylamino)-3,4-dihydropyrido[3,2-d]pyrimidin-2-yl)but-3-ynylamino)propylcarbamate.
  • Figure imgb0100
  • To a solution of (R)-2-(1-aminobut-3-ynyl)-3-(phenylamino)pyrido[3,2-d]pyrimidin-4(3H)-one (500 mg, 1.46 mmol) and diisopropylethylamine (638 µl, 3.66 mmol) in 1,2-dichloroethane (20 ml) was added 3-[(benzyloxyxarbonyl)amino]propionaldehyde (303 mg, 1.46 mmol) and sodium triacetoxyborohydride (620 mg, 2.93 mmol). The reaction was stirred at room temperature for 2 hours before 10 ml of sodium carbonate was added. 200 ml of 1,2-dichloroethane and 40 ml of water were added to the reaction mixture. The organic layer was separated and washed with brine (50 ml), dried over Na2SO4 and concentrated to dryness under reduced pressure. The crude produce was purified by flash silica gel chromatography eluting with CH2Cl2/CH3OH (18 : 1) to afford (R)-benzyl 3-(1-(4-oxo-3-(phenylamino)-3,4-dihydropyrido[3,2-d]pyrimidin-2-yl)but-3-ynylamino)propyl carbamate (365 mg, 50 %) as a off-white solid, M.p. 75-77 °C. LCMS: m/e 497 [M+H]. 1H NMR (CDCl3): δ 8.85 (dd, J = 6.4 Hz and 1.6 Hz, 1H), 8.12 (d, J= 8 Hz, 1H), 7.65 (br, 1H), 7.31 (m, 5H), 7.23 (t, J= 8.4 Hz, 3H), 6.99 (t, J = 7.2 Hz, 1H), 6.72 (d, J = 7.6 Hz, 2H), 5.61 (s, 1H), 5.07 (m, 2H), 4.29 (s, 1H), 3.37-3.22 (m, 2H), 2.74 (s, 2H), 2.52 (m, 2H), 1.03 (m, 4H).
    • Example 97: (R)-Benzyl 3-(3-chloro-2-fluoro-N-(1-(4-oxo-3-(phenylamino)-3,4-dihydropyrido[3,2-d]pyrimidin-2-vl)but-3-ynyl)benzamido)propylcarbamate.
  • Figure imgb0101
  • To a solution of (R)-benzyl 3-(1-(4-oxo-3-(phenylamino)-3,4-dihydropyrido[3,2-d]pyrimidin-2-yl)but-3-ynylamino)propylcarbamate (130 mg, 0.262 mmol) and diisopropylethylamine (50 µl, 0.288 mmol) in dichloromethane (anhydrous, 2.0 ml) was added 3-chloro-2-fluorobenzoyl chloride (55 mg, 0.288 mmol). The reaction was carried out at room temperature for 10 minutes. 150 ml of dichloromethane was added to the reaction mixture, then washed with sat.NaHCO3 solution (30 ml), water (30 ml), and brine (30 ml), dried over Na2SO4 and concentrated to dryness under reduced pressure. The crude produce was purified by flash silica gel chromatography eluting with hexanes/EtOAc (1 : 1) to afford (R)-benzyl 3-(3-chloro-2-fluoro-N-(1-(4-oxo-3-(phenylamino)-3,4-dihydropyrido[3,2-d]pyrimidin-2-yl)but-3-ynyl)benzamido)propylcarbamate (125 mg, 74 %) as a pale yellow solid, M.p. 100-102 °C. LCMS: m/e 653 [M+H]. 1H NMR (CDCl3): δ 8.88 (d, J = 2.8 Hz, 1H), 8.15 (d, J = 8.8 Hz, I H), 7.70 (m, 1H), 7.35 (m, 6H), 7.23 (m, 2H), 7.08 (t, J= 7.2 Hz, 2H), 6.88 (s, 1H), 6.51 (s, 2H), 5.25 (s, 1H), 5.13-4.99 (m, 2H), 3.77 (m, 1H), 3.51 (m, 1H), 3.30-3.14 (m, 2H), 2.05 (m, 1H), 1.64 (s, 1H), 1.45 (m, 2H), 1.26 (m, 2H).
    • Example 98: (R)-N-(3-Aminopropyl)-3-chloro-2-fluoro-N-(1-(4-oxo-3-(phenylamino)-3,4-dihydropyrido[3,2-d]pyrimidin-2-yl)but-3-ynyl)benzamide (83).
  • Figure imgb0102
  • To a solution of (R)-benzyl 3-(3-chloro-2-fluoro-N-(1-(4-oxo-3-(phenylamino)-3,4-dihydropyrido[3,2-d]pyrimidin-2-yl)but-3-ynyl)benzamido)propylcarbamate (100 mg, 0.153 mmol) in acetonitrile (2 ml) was slowly added iodotrimethylsilane (83 µl, 0.613 mmol) at 0 °C. After stirring for 10 minutes, 0.5 ml of sat.NaHCO3 solution was added to quench the reaction. 100 ml of dichloromethane was added to the reaction mixture, then washed with water (30 ml), brine (30 ml), dried over Na2SO4 and concentrated to dryness under reduced pressure. The crude product was purified by preparative HPLC. The resulted product (TFA salt) was dissolved in dichloromethane (100 ml) and washed with sat.NaHCO3 solution (20 ml), sat.NaCl solution (20 ml), dried over Na2SO4 and concentrated to dryness under reduced pressure. To a solution of the residue in EtOAc (2 ml) was added HCl:EtOAc (3.0 M, 1.0 ml). The mixture was stirred at room temperature for 30 minutes and concentrated to afford (R)-N-(3-aminopropyl)-3-chloro-2-fluoro-N-(1-(4-oxo-3-(phenylamino)-3,4 dihydropyrido[3,2-d]pyrimidin-2-yl)but-3-ynyl)benzamide (40 mg, 44 %, 2HCl) as a pale yellow solid, M.p. 198-200 °C. LCMS: m/e 519 [M+H]. 1H NMR (CD3OD): δ 8.93 (s. 1H), 8.59 (d, J= 8.0 Hz, 1H), 8.12 (s, 1H), 7.52 (s, 1H), 7.27 (d, J= 6.4 Hz, 2H), 7.10 (s, 2H), 7.00 (m, 1H), 6.85 (s, 1H), 6.53 (s, 1H), 6.38 (s, 1H), 5.51 (s, 1H), 5.26 (s, 1H), 3.73-3.59 (m, 2H), 2.65-2.29 (m, 2H), 2.01-1.59 (m, 2H), 1.19 (m, 4H).
    • Example 99: (R)-N-(3-Aminopropyl)-2,3-difluoro-4-methyl-N-(1-(4-oxo-3-(phenylamino)-3,4-dihydropyrido[3,2-d]pyrimidin-2-yl)but-3-ynyl)benzamide (84).
  • Figure imgb0103
  • This compound was synthesized as described in general procedure E, except 2,3,-di-fluoro-4-methy benzoyl chloride was used instead of 2-fluoro-3-chloro benzoyl chloride as a yellow solid, M.p. 185-187°C. LCMS: m/e 517 [M+H]. 1H NMR (DMSO-d6): δ 9.18 (m, 1H), 8.87 (m, 1H), 8.31 (m, 1H), 7.95 (m, 1H), 7.78 (s, 1H), 7.21 (m, 1H), 7.08 (m, 1H), 6.84 (m, 2H), 6.52 (d, J = 8.0 Hz, 1H), 6.33 (m, I H), 5.23 (s, I H), 4.99 (m, 1H), 4.18 (s, 2H), 3.47 (m, 1H), 3.24 (m, 1H), 2.91 (m, 1H), 2.72 (m, 1H), 2.33 (m, 2H), 2.05 (s, 3H), 1.67 (m, 2H).
    • Example 100: (R)-N-(3-Aminopropyl)-2,6-difluoro-3-methyl-N-(1-(4-oxo-3-(phenylamino)-3,4-dihydropyrido[3,2-d]pyridin-2-yl)but-3-ynyl)benzamide (85).
  • Figure imgb0104
  • This compound was synthesized as described in general procedure E, except 2,6,-di-fluoro-3-methy benzoyl chloride was used instead of 2-fluoro-3-chloro benzoyl chloride as a yellow solid, M.p. 198-200 °C. LCMS: m/e 517 [M+H]. 1H NMR (DMSO-d6): δ 9.14 (m. 1H), 8.88 (m, 1H), 8.31 (m, 1H), 7.96 (m, 1H), 7.81 (s, 1H), 7.12 (m, 2H), 6.85 (m, 2H), 6.60 (d,J= 7.6 Hz, 1H), 6.28 (m, 1H), 5.99 (m, 1H), 5.08 (m, 1H), 3.76 (s, 2H), 3.38-3.21 (m, 2H), 3.18 (m, 1 H), 2.92 (m, 1H), 2.26 (s, 2H), 2.12 (s, 1H), 2.03 (s, 1H), 1.98 (s, 1H), 1.24 (s, 2H).
    • Example 101: (R)-N-(3-Aminopropyl)-2,3,4,5-tetrafluoro-N-(1-(4-oxo-3-(phenylamino)-3,4-dihydropyrido[3,2-d]pyrimidin-2-yl)but-3-ynyl)benzamide (86).
  • Figure imgb0105
  • This compound was synthesized as described in general procedure E, except 2,3,4,5-tetra-fluoro benzoyl chloride was used instead of 2-fluoro-3-chloro benzoyl chloride as a pale yellow solid, M.p. 180-182 °C. LCMS: m/e 539 [M+H]. 1H NMR (DMSO-d6): δ 9.24 (m. 1H), 8.89 (m, 1H), 8.31 (m, 1H), 7.96-7.71 (m, 3H), 7.20 (m, 1H), 7.13 (m, 1H), 6.94-6.67 (m, 1H), 6.58 (d, J = 8.0 Hz, 1H), 5.40 (br, 3H), 3.50 (m, 1H), 3.45 (m, 1H), 3.29 (m, 2H), 3.20 (m, 1H), 2.71 (m, I H), 1.82-1.54 (m, 2H), 1.30-1.20 (m, 2H).
    • Example 102: Fluorescence detection of HsEg5 ATPase activity and compound inhibition
  • Purified HsEg5 motor fragment was activated by mixture with preformed MT polymer (Cytoskeleton, Denver, CO) at room temperature for 20 minutes. MT activated ATPase activity was measured using ADP Quest (DiscoverX, Fremont, CA) in which a coupled-enzyme assay can translate accumulation of ADP into detectable resorufin signal (Figure 1A). Fluorescence was measured at λEx=535 nm and λEm=590 nm on a Wallac Victor 2 plate reader (Perkin-Elmer Life Sciences, Boston, MA). Reagent A and B from ADP Quest kit were aliquoted and frozen in - 20°C before use. A standard curve was determined using the provided ADP reagent in the reaction buffer that consisted of 50 mM Pipes (pH7.0), 5.0 mM MgCl2, 20 µM paclitaxel and 0.5 µM tubulin. The same buffer was used for Km determination with HsEg5 concentration of 10 nM.
  • For inhibitor screening, 4 µL of compounds were incubated with 10 µL of MT-activated HsEg5 such that the final concentrations for compound range from 100 µM to 5 nM (1 to 3 serial dilutions, final concentration) and final concentration for HsEg5 is 10 nM. The mixture was incubated at room temperature for 10 minutes with mild shaking. The screening assay contained 0.3% DMSO in all reaction wells. We used wells containing only DMSO as negative controls and wells without ATP as background. Addition of 6 µL ATP (final concentration of 20 µM) initiated the ATP hydrolysis reaction. The 20 µL-reaction was allowed to proceed at room temperature for 10 minutes before addition of 10 µL of reagent A and 20 µL of reagent B. After 20-minute development at room temperature, the fluorescence was measured and data analysis was performed using GraphPad Prism version 3.0 (GraphPad Software, San Diego, CA)
    • Example 103: Robotic settings for high-throughput screening
  • For the purpose of high-throughput screening, we automated the fluorescence assay using a Sciclone ALH3000 (Caliper Life Sciences, Hopkinton, MA) and Multidrop 384 (Thermo Electron Corp, Waltham, MA). First, compound dilution plates for screening (at 10 µM or 1 µM) and IC50 determination (10 data points from 100 µM to 5 nM) were made in Coming polypropylene V-bottom 96-well plates. In both cases, the 1st and 7th column contained background (No ATP addition) and negative control (DMSO only). For screening compounds at 10 µM or 1 µM, 4 µl of each compound at 50 µM or 5 µM were used in a 20 µL assay reaction. For IC50 determination, the mother compound plate contained 24 µL of tested compound at stock concentration of 30 mM. 6 µL of each test compound in 30 mM was added to each well in the column 2 and followed by 1:3 serial dilutions in DMSO with the Sciclone ALH3000. 234 µL of assay buffer was then added using a Multidrop 384. Then 4 µL of diluted compounds was used in 20 µL-reaction. The final concentration was a 1:300 dilution of the original stock. Second, a reagent source plate was prepared with three rows designated to MT-activated HsEg5, Reagent A and Reagent B respectively. MTs were diluted with assay buffer and polymerized at room temperature for 10 minutes. Just before use, HsEg5 protein was thawed on ice and activated by addition of MT polymers at room temperature for 20 minutes. HsEg5/MT was then added to Row A of the reagent source plate. The final assay concentration was 10 nM HsEg5 and 500 nM MTs. Reagent A and B were stored at -20°C and thawed at room temperature followed by transferring to rows B & C of the reagent source plate. Third, ATP substrate plate was prepared by transferring 80 µM ATP solution to each well of a V-shape 96-well plate except the wells in the first row where assay buffer was added instead to have no-ATP blanks. The final concentration for ATP in the assay was 20 µM.
  • The assay was programmed on Sciclone ALH3000 with the following procedures: 1) Addition of 4 µL compounds to the assay plate, followed by addition of 10 µL of MT-activated HsEg5. The mixture was incubated at room temperature for 10 minutes with occasionally shaking; 2) HsEg5 ATPase reaction was initiated by addition of 6 µL of ATP and proceeded at room temperature for 10 minutes. 3) Addition of 10 µL reagent A and 20 µL reagent B to the plate and incubation at room temperature for exactly 20 minutes. The fluorescence was measured at Wallac Victor 2 multilabel counter with excitation and emission wavelength stated previously.
    • Example 104: Luminescent detection of HsEg5 ATPase activity and compound inhibition
  • Purified HsEg5 motor fragment was activated by mixture with preformed MT polymer (Cytoskeleton, Denver, CO) at room temperature for 20 minutes. MT activated ATPase activity was measured using Kinase-Glo® Plus Luminescent Kinase Assay (Promega, Madison, WI).
  • For inhibitor screening, 5 µL of compounds were incubated with 20 µL of MT-activated HsEg5 such that the final concentrations for compound range from 100 µM to 5 nM (1 to 3 serial dilutions, final concentration) and final concentration for HsEg5 is 25 nM. The mixture was incubated at room temperature for 20 minutes with mild shaking. The screening assay contained 0.3% DMSO in all reaction wells. We used wells containing only DMSO as negative controls and wells without ATP as background. Addition of 15 µL of 13 µM ATP (final concentration of 5 µM) initiated the ATP hydrolysis reaction. The 40 µL-reaction was allowed to proceed at room temperature for 45 minutes before addition of 40 µL of Kinase®-Glo Plus. After 15-minute development at room temperature, the luminescent was measured.
    • Example 105: MTS Assay
  • Cell viability was determined by measuring the activity of dehydrogenase enzymes in metabolically active cells using a tetrazolium compound, MTS. The assay was performed as described in Promega Technical Bulletin No. 169 (CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay). Two human cancer cell lines were assayed (see. Table 1). Cells were maintained at 37°C and 5% CO2 in DMEM media (4.5 g/L glucose) supplemented with 10% heat-inactivated FBS, 10 mM L-glutamine, and 10 mM Hepes pH 7.5. Briefly, cells were seeded in 96-well plates as set forth in Table 1 and incubated for 16-24 hours. Candidate compounds were serially diluted in DMSO, further diluted in cell culture media, and then added to cells (final DMSO concentration of 0.33%). Cells were incubated in the presence of candidate compound for 72 hours. MTS stock solution (MTS 2 gm/L, PMS 46.6 mg/ml in PBS) was added to the cells (final concentration MTS 2 gm/L and PMS 7.67 mg/L) and incubated for 4 hours. SDS was added to a final concentration of 1.4% and absorbance at 490 nM was measured within two hours using a plate reader. The IC50 was defined as the concentration of compound that results in a 50% reduction in the number of viable cells as compared to control wells treated with DMSO only (0.33%) and was calculated using non-linear regression analysis. IC50 values were given in Table 2 for the compounds listed. The Compound Numbers in Table 2 correspond to the numbers listed parenthetically in the Example titles. Table 1
    Cell Line Cancer Type Cells/well
    A549 non small cell lung 400
    NCI-H460 non small cell lung 180
    Table 2
    Compound Number Molecular weight Eg5 IC50* (µM) MTS NCI H460 IC50 (µM) MTS NCI A549 IC50 (µM)
    1 552.43 0.028 0.36 0.42
    2 568.90 0.645 1.75 2.37
    3 504.03 0.702 1.19 2.3
    4 524.45 0.72 1.14 2.4
    5 535.00 1.05 2.39 4.4
    6 558.89 0.418 1.16 1.87
    7 525.98 0.566 1.77 2.57
    8 507.99 2.13 2.83 4.75
    9 525.98 1.16 2.39 3.57
    10 543.97 0.599 1.14 2.36
    11 55 8.89 0.735 2.44 3.01
    12 558.89 0.818 2.11 3.37
    13 542.44 0.749 2.21 3.57
    14 568.90 1.0 3.25 3.44
    15 615.90 1.65 2.27 3.08
    16 522.02 1.15 0.929 1.36
    17 540.01 1.6 1.59 2.56
    18 522.02 1.25 2.5 3.92
    19 542.44 0.582 0.894 1.57
    20 560.43 0.844 1.0 1.8
    21 540.01 1.25 1.08 1.93
    22 541.05 1.61 1.17 2.08
    23 556.07 1.02 1.12 2.49
    24 522.02 1.05 1.09 1.79
    25 522.02 1.43 0.959 1.52
    26 540.01 0.944 0.889 1.25
    27 504.03 1.28 1.08 2.22
    28 483.61 1.59 1.35 2.5
    29 505.02 2.17 2.09 3.31
    30 550.05 NA 12.0 7.1
    31 544.05 1.43 NA 10.8
    32 519.04 1.39 0.956 1.87
    33 558.10 4.22 10.4 NA
    34 532.09 1.65 5.47 6.36
    35 554.04 1.96 6.15 4.52
    36 586.95 1.86 3.77 4.37
    37 570.49 1.66 4.49 5.02
    38 588.53 4.59 3.59 NA
    39 586.10 3.01 4.49 6.09
    40 602.16 2.83 8.35 6.12
    41 544.87 3.37 6.28 5.67
    42 540.01 0.476 2.08 4.28
    43 522.02 0.833 2.81 3.49
    44 582.93 1.85 13.4 13.8
    45 574.46 0.743 3.17 3.24
    46 536.05 0.246 0.678 NA
    47 555.08 3.23 2.7 4.09
    48 637.00 2.57 4.36 4.93
    49 572.13 3.44 4.41 4.69
    50 594.08 1.18 3.12 3.77
    51 576.09 2.8 5.38 4.45
    52 594.08 1.25 3.47 4.29
    53 610.54 2.62 4.44 5.26
    54 636.96 2.41 11.9 12.2
    55 622.04 4.16 16.1 33.7
    56 570.42 0.138 1.86 3.82
    57 552.43 0.0506 0.766 0.433
    58 610.98 3.69 5.55 5.88
    59 532.08 52.3 4.24 NA
    60 510.42 3.99 10 NA
    61 490.00 3.89 12.5 14.2
    62 525.98 3.74 22.8 21.7
    63 507.99 3.34 10.5 7.02
    64 528.41 1.46 6.81 12.6
    65 525.98 4.08 11.4 12.4
    66 500.05 NA 3.20 2.35
    67 490.05 8.3 13.1 15.5
    68 490.05 NA 2.59 3.86
    69 508.04 NA 3.77 3.9
    70 476.02 NA 4.23 6.91
    71 571 0.16 0.32 0.84
    72 571 0.04 0.33 0.62
    73 555 0.12 0.33 0.49
    74 565 5.90 1.23 1.80
    75 513 0.09 1.50 2.80
    76 549 0.13 0.86 1.30
    77 565 0.07 0.53 0.86
    78 565 0.04 0.70 1.45
    79 570 0.55 0.43 1.30
    80 535 0.09 0.10 0.58
    81 553 0.16 0.34 0.66
    82 535 0.03 NA NA
    83 517 6.60 27.0 >100
  • -Eg5 IC50 data was generated using both fluorescence and Luminescence detection assays as described above. Compounds 1-69 were screened using automated fluorescence assay while compounds 70-83 were screened using Luminescence detection assay. (See reference "Zhang B, Senator D, Wilson CJ, Ng SC. (2005) "Development of a high-throughput robotic fluorescence-based assay for HsEg5 inhibitor screening" Anal Biochem. 345:326-335").
    • Example 106: In vivo Data
  • Six-week old female athymic nude mice (NCR nu/nu; Charles River Laboratory, Wilmington, MA) were acclimated to the animal housing facility for at least 1 week before the study. Efficacy studies were performed in athymic mice bearing PACA2 tumor xenografts to determine the effect of compound on tumor growth. Tumor cells (1 × 107 PACA2 cells/animal) were inoculated subcutaneously on day 0. Tumor dimensions were measured by a digital microcaliper, and tumor volumes were calculated as length × width2/ 2. When tumors reached a volume of ~100 mm3, mice were randomized into groups and treated 3 × weekly (Monday-Wednesday-Friday, followed by a 2-day dosing holiday) intraperitoneally with either vehicle control or 6.25 and 12.5 mg/kg compound formulated in PEG400:40% Water:60% at 10 mg/ml for a total of 4 weeks. Results are expressed as mean tumor volume ± SE. To assess differences in tumor size between groups, a Mann-Whitney non-parametric t test was performed and significance was assessed for p values <0.05. Tumor size was evaluated periodically during treatment at the indicated days post-inoculation. Results are represented as the mean of tumor volume in mm3 ± SE of several tumors (n=10) in function of the treatment period. Significant reductions in tumor growth were observed in groups treated with well-tolerated doses of 6.25 or 12.5 mg/kg of N-(3-amino-propyl)-3-chloro-N-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-2-fluoro-benzamide on PACA-2 xenograft model compared to the vehicle control group. (See Fig. I A).
    • Example 107: In vivo Data
  • Six weeks old female athymic nude mice (NCR nu/nu) received from Charles River Laboratory, acclimated to the animal housing facility for one week before initiation of the study. Mice were housed in sterile cages of 4 each with autoclaved bedding, provided with autoclaved food and water ad libitum. Efficacy studies were performed in athymic mice bearing PACA2 tumor xenografts to determine the effect of compound on tumor growth. Tumor cells (1 × 107 PACA2 cells/animal) were inoculated subcutaneously on day 0. Tumor dimensions were measured three times weekly by a digital microcaliper, and tumor volumes were calculated as length × width2/2. When tumors reached a volume of ~300 mm3, mice were randomized into groups and treated 3× weekly (Monday-Wednesday-Friday, followed by a 2-day dosing holiday) intraperitoneally. With either vehicle control or 3mg/kg and 12.5 mg/kg compound formulated in DMA/PEG400/water (20:40:40). Results are expressed as mean tumor volume ± SE. To assess differences in tumor size between groups, student's t test was performed and significance was assessed for p values <0.05. Tumor size was evaluated periodically during treatment at the indicated days post-inoculation. Results are represented as the mean of tumor volume in mm3 ± SE of several tumors (n=10) in function of the treatment period. Significant reductions in tumor growth were observed in groups treated with well-tolerated doses of 3 mg/kg or 12.5 mg/kg ofN-(3-amino-propyl)-3-chloro-N-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-2-fluoro-benzamide on PACA-2 xenograft model compared to the vehicle control group. (See Figure I B).
    • Example 108: In vivo Data
  • Six weeks old female athymic nude mice (NCR nu/nu) received from Charles River Laboratory, acclimated to the animal housing facility for one week before initiation of the study. Mice were housed in sterile cages of 4 each with autoclaved bedding, provided with autoclaved food and water ad libitum. Efficacy studies were performed in athymic mice bearing MDA-MB-231 tumor xenografts to determine the effect of compound on tumor growth. Tumor cells (5 × 106 MDA-MB-231 cells/animal) were inoculated subcutaneously on day 0. Tumor dimensions were measured three times weekly by a digital microcaliper, and tumor volumes were calculated as length × width2/2. When tumors reached a volume of ~100 mm3, mice were randomized into groups and treated 3 × weekly (Monday-Wednesday-Friday, followed by a 2-day dosing holiday) intraperitoneally. With either vehicle control or 3 mg/kg, 6 mg/kg and 12 mg/kg compound formulated in DMA/PEG400/water (4:8:88). Results are expressed as mean tumor volume ± SE. To assess differences in tumor size between groups, student's t test was performed and significance was assessed for p values <0.05. Tumor size was evaluated periodically during treatment at the indicated days post-inoculation. Results are represented as the mean of tumor volume in mm3 ± SE of several tumors (n=8) in function of the treatment period. Significant reductions in tumor growth were observed in groups treated with well-tolerated doses of 3 mg/kg, 6mg/kg or 12 mg/kg of N-(3-amino-propyl)-3-chloro-N-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-2-fluoro-benzamide on MDA-MB-231 xenograft model compared to the vehicle control group (See Figure 2).

Claims (27)

  1. A compound of formula I, or pharmaceutically acceptable salts thereof:
    Figure imgb0106
     wherein
    m, n and A are independently selected from the group consisting of 0, 1, 2, 3, and 4.
    R1 is selected from the group consisting of H, alkyl, aryl, substituted aryl, haloaryl, fluoroaryl, bi aryl, or bis aryl, alkenyl, alkynyl, heteroaryl, cycloalkyl, heterocyclyl, haloalkyl and perfluoroalkyl;
    Y is selected from the group consisting of a bond, -C=O, -S=O, and -S(O)2;
    X is selected from the group consisting of NR2, O, S and CHR2; R1 and R2, taken together, may form a ring;
    R2 is selected from the group consisting of hydrogen, alkyl including lower alkyl, aryl, alkenyl, alkynyl, heteroaryl, alkylheteroaryl, cycloalkyl, heterocyclyl, and perfluoroalkyl;
    R3 is selected from H, alkyl, aryl, substituted aryl, alkylaryl, heteroaryl, perfluoroalkyl, alkenyl, and alkynyl;
    R4 is alkynyl;
    Each R5 and each R6 are independently selected from the group consisting of H, halogen, hydroxyl, nitrogen, amino, cyano, alkoxy, alkylthio, methylenedioxy, or haloalkyloxy; or alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylamino, dialkylamino, alkylsulfonyl, arylsulfonyl, alkylcarboxy, carboxyamino, carboxyamido, aminocarbonyl, and alkylsulfonamido;
    Q is either absent or selected from the group consisting of -CO, -COO, -CONR11, -C (=S), -CH2, -SO, and -SO2;
    R7 is selected from the group consisting of hydrogen, alkyl, aryl, alkylaryl, heteroaryl, aryls substituted with heterocycles;
    W is selected from H or NR8R9; where R8 and R9 are independently selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, alkenyl, akynyl, COR13, -CO2R13, - CONR14R14, -SOR13, -SO2R13, -C(=S)R14, -C(=NH)R14, and -C(=S)NR14R15; or R8 and R9 together with the N they are bonded to optionally form a heterocycle or substituted heterocycle;
    Each Z is C;
    Each R10 is independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, amino, cyano, alkoxy, alkylthio, methylenedioxy, or haloalkyloxy; alkyl, alkenyl, alkynyl, aryl, substituted aryl, heteroaryl, alkylamino, dialkylamino, alkylsulfonyl, arylsulfonyl, alkylcarboxy, carboxyamino, carboxyamido, aminocarbonyl, and alkylsulfonamido;
    R11, R12, R13, R14, and R15 are independently selected from the group consisting of hydrogen, alkyl, aryl, alkylaryl, heteroaryl, oxaalkyl, oxaalkylaryl, and substituted oxaalkylaryl.
  2. The compound of claim 1, wherein A is 1 or 2 and R5 and R6 are independently selected from the group consisting of H, halogen, hydroxyl, nitrogen, amino, cyano, alkoxy, alkylthio, methylenedioxy, or haloalkyloxy; or alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylamino, dialkylamino, alkylsulfonyl, arylsulfonyl, alkylcarboxy, carboxyamino, carboxyamido, aminocarbonyl, and alkylsulfonamido.
  3. The compound of claim 1 wherein A is 1, and R5 and R6 are H.
  4. The compound of claim 1 wherein R8 and R9 are H.
  5. The compound of claim 1 wherein X is NH2.
  6. The compound of claim 1 wherein X is ethynyl.
  7. The compound of claim 1 wherein R1 is phenyl.
  8. The compound of claim 1 wherein R4 is ethynyl.
  9. The compound of claim 1 wherein R5 and R6 are H.
  10. The compound of claim 1 wherein Q is CO, CH2, CHR12, or SO2.
  11. The compound of claim 1 wherein R7 is unsubstituted or substituted phenyl.
  12. The compound of claim 1 wherein W is H.
  13. The compound of claim 1 wherein R8 and R9 are H.
  14. The compound of claim 1 wherein the compound is selected from the group consisting of N-(3-Amino-propyl)-3-chloro-N-[(R)- 1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-2-fluoro-benzamide, 2-{(R)-1-[(3-Amino-propyl)-(4-methyl-benzyl)-amino]-but-3-ynyl}-7-chloro-3-phenylamino-3H-quinazolin-4-one, N-(3-Amino-propyl)-N-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydro-quinazolin-2-yl)-but-3-ynyl]-4-methyl-benzenesulfonamide, N-(3-Amino-propyl)-N-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydroquinazolin-2-yl-but-3-ynyl]-2,3,5,6-tetraflubro-benzamide, (R)-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,3,4,5-tetrafluorobenzamide, N-(3-Aminopropyl)-3-chloro-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)pent-3-ynyl)-2-fluorobenzamide, N-(3-Amino-propyl)-N-[(R)-1-(7-chloro-4-oxo-3-phenylamino-3,4-dihydroquinazolin-2-yl)-but-3-ynyl]-2,3-difluoro-4-methyl-benzamide, (R)-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,3-difluoro-6-methoxybenzamide, (R)-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,3-difluoro-4-methoxybenzamide, (R)-N-(3-Aminopropyl)-4-chloro-N-(1-(7-chloro-4-oxo-3-phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,6-difluoro-benzamide, (R)-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-3,5-difluorobenzamide, (R)-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,3,5-trifluorobenzamide, (R)-N-(3-Aminopropyl)-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-ynyl)-2,3-difluorobenzamide.
  15. A pharmaceutical composition comprising a compound of claim 1 in combination with a pharmaceutically acceptable carrier or excipient.
  16. The pharmaceutical composition of claim 15 further comprising a second chemotherapeutic agent.
  17. The pharmaceutical composition of 16, wherein said second chemotherapeutic agent is selected from the group consisting of tamoxifen, raloxifene, anastrozole, exemestane, letrozole, cisplatin, carboplatin, paclitaxel, cyclophosphamide, lovastatin, minosine, gemcitabine, araC, 5-fluorouracil, methotrexate, docetaxel, goserelin, vincristin, vinblastin, nocodazole, teniposide, etoposide, epothilone, navelbine, camptothecin, daunonibicin, dactinomycin, mitoxantrone, amsacrine, doxorubicin, epirubicin, idarubicin imatanib, gefitinib, erlotinib, sorafenib, sunitinib malate, trastuzumab, rituximab, cetuximab, and bevacizumab.
  18. The compound of formula I as defined in claim 1, or pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable carrier for use in the treatment of a cell proliferative disorder.
  19. The compound for use of claim 18, wherein said cell proliferative disorder is a precancerous condition.
  20. The compound for use of claim 18, wherein said cell proliferative disorder is a cancer.
  21. The compound for use of claim 18, wherein said cancer is adenocarcinoma, squamous carcinoma, sarcoma, lymphoma, multiple myeloma, or leukemia.
  22. The compound for use of claim 18, wherein said cancer is lung cancer, colon cancer, breast cancer, pancreatic cancer, prostate cancer, acute leukemia, chronic leukemia, multiple melanoma, ovarian cancer, malignant glioma, leiomyosarcoma, hepatoma, or head and neck cancer.
  23. The compound for use of claim 18, wherein said compound of formula I, or a pharmaceutically acceptable salt thereof, or a prodrug or metabolite thereof, is administered in combination with a second chemotherapeutic agent.
  24. The compound for use of claim 23, wherein said second chemotherapeutic agent is selected from the group consisting of tamoxifen, raloxifene, anastrozole, exemestane, letrozole, cisplatin, carboplatin, paclitaxel, cyclophosphamide, lovastatin, minosine, gemcitabine, araC, 5-fluorouracil, methotrexate, docetaxel, goserelin, vincristin, vinblastin, nocodazole, teniposide, etoposide, epothilone, navelbine, camptothecin, daunonibicin, dactinomycin, mitoxantrone, amsacrine, doxorubicin, epirubicin, idarubicin imatanib, gefitinib, erlotinib, sorafenib, sunitinib malate, trastuzumab, rituximab, cetuximab, and bevacizumab.
  25. The compound for use of claim 18, wherein said treating cancer comprises a reduction in tumor size, a delay of tumor growth, an improvement in the survival of patients, or an improvement in the quality of patient life.
  26. The compound for use of claim 18, wherein the cancer is primary cancer or metastatic cancer.
  27. The compound of claim 1 wherein stereochemistry is of "R" configuration.
EP08771527A 2007-06-22 2008-06-19 Quinazolinone compounds and methods of use thereof Active EP2173724B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94583807P 2007-06-22 2007-06-22
PCT/US2008/067571 WO2009002808A2 (en) 2007-06-22 2008-06-19 Quinazolinone compounds and methods of use thereof

Publications (2)

Publication Number Publication Date
EP2173724A2 EP2173724A2 (en) 2010-04-14
EP2173724B1 true EP2173724B1 (en) 2012-12-05

Family

ID=39846620

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08771527A Active EP2173724B1 (en) 2007-06-22 2008-06-19 Quinazolinone compounds and methods of use thereof

Country Status (13)

Country Link
US (1) US8232285B2 (en)
EP (1) EP2173724B1 (en)
JP (1) JP2010530885A (en)
KR (1) KR20100024494A (en)
CN (1) CN101801937A (en)
AU (1) AU2008268613A1 (en)
BR (1) BRPI0813355A2 (en)
CA (1) CA2704282A1 (en)
IL (1) IL202740A0 (en)
MX (1) MX2009013815A (en)
TW (1) TW200918069A (en)
WO (1) WO2009002808A2 (en)
ZA (1) ZA201000183B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268807B2 (en) * 2010-04-19 2012-09-18 Sri International Compositions and method for the treatment of multiple myeloma
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20150132575A1 (en) * 2013-11-14 2015-05-14 Honeywell International Inc. Luminescent fibers, articles including the same, and methods of forming the same
CN106456628A (en) 2014-03-19 2017-02-22 无限药品股份有限公司 Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2998469A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TW201825465A (en) 2016-09-23 2018-07-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201815787A (en) 2016-09-23 2018-05-01 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201813963A (en) 2016-09-23 2018-04-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
CN118206551A (en) * 2018-05-11 2024-06-18 美国卫生和人力服务部 Quinoline compounds, their preparation and their use as antimalarial agents
CN113354590A (en) * 2020-03-05 2021-09-07 宁波康柏睿格医药科技有限公司 Quinazolinone compound for antagonizing NOD1/2 receptor signal pathway

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723432A (en) * 1968-11-12 1973-03-27 Sandoz Ag 1-substituted-4-aryl-2(1h)-quinazolinones and their preparation
AU543928B2 (en) 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5187167A (en) * 1986-03-27 1993-02-16 Imperial Chemical Industries Plc Pharmaceutical compositions comprising quinazolin-4-one derivatives
GB8707053D0 (en) * 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
SK278989B6 (en) * 1988-02-10 1998-05-06 F. Hoffmann-La Roche Ag Substituted pyrroles, their use for producing a drug, and the drug on their base
GB8827820D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
GB8827988D0 (en) * 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
USRE36736E (en) * 1989-02-06 2000-06-13 Hoffman-La Roche Inc. Substituted pyrroles
MC2096A1 (en) 1989-02-23 1991-02-15 Hoffmann La Roche SUBSTITUTED PYRROLES
GB8904161D0 (en) * 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
PT93947B (en) 1989-05-05 1996-11-29 Goedecke Ag METHOD FOR PREPARING NEW DENTURES OF MALEINIMIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
DE4005969A1 (en) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh NEW TRISUBSTITUTED PYRROLE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE4005970A1 (en) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh NEW TRISUBSTITUTED MALEINIMIDES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
ZA913730B (en) * 1990-05-30 1992-02-26 Ici Plc Anti-tumor compounds
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
US5591842A (en) * 1991-11-29 1997-01-07 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives
SK281423B6 (en) 1992-03-12 2001-03-12 Smithkline Beecham Plc Condensed indole derivatives and process for their preparation and pharmaceutical compositions them containing and their use
JPH07504673A (en) 1992-03-20 1995-05-25 ザ・ウエルカム・ファウンデーション・リミテッド Indole derivatives with antiviral activity
US5721230A (en) * 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
ES2236702T3 (en) 1993-12-23 2005-07-16 Eli Lilly And Company INHIBITORS OF PROTEIN QUINASA C.
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
AU2096895A (en) * 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
WO1995030682A1 (en) 1994-05-09 1995-11-16 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyprolocarbazole derivative
IL110831A (en) 1994-08-31 1998-12-27 Hadasit Med Res Service Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
IL112125A (en) 1994-12-22 1998-02-08 Hadasit Med Res Service Quinazolinone-containing pharmaceutical compositions
US5559228A (en) * 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
WO1997034890A1 (en) 1996-03-20 1997-09-25 Eli Lilly And Company Synthesis of indolylmaleimides
PE91698A1 (en) 1996-07-29 1998-12-24 Hoffmann La Roche SUBSTITUTED PYRROLES
PE91598A1 (en) 1996-07-29 1998-12-24 Hoffmann La Roche SUBSTITUTED PYRROLES
PL331899A1 (en) 1996-08-23 1999-08-16 Lilly Co Eli Method of obtaining bis-indolyl malimides
SE9603283D0 (en) * 1996-09-10 1996-09-10 Astra Ab New compounds
AU4920397A (en) 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US6028075A (en) 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
US5859261A (en) * 1997-03-20 1999-01-12 Eli Lilly And Company Synthesis of indolylmaleimides
US6184377B1 (en) * 1997-12-15 2001-02-06 Sepracor Inc. Compositions containing N-amino- and N-hydroxy-quinazolinones and methods for preparing libraries thereof
KR20010085305A (en) 1998-07-30 2001-09-07 미즈노 마사루 Disubstituted maleimide compounds and medicinal utilization thereof
EP1152002A4 (en) 1999-02-09 2002-04-17 Sagami Chem Res PYRROLE DERIVATIVES AND CELL DEATH INHIBITORS
NZ518480A (en) 1999-10-27 2004-02-27 Cytokinetics Inc Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
UA74803C2 (en) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
DE60010934T2 (en) 1999-12-16 2005-05-19 Eli Lilly And Co., Indianapolis Medicines suitable for the treatment of proliferative diseases
WO2001044247A2 (en) 1999-12-16 2001-06-21 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
EP1275646A4 (en) 2000-03-30 2003-05-28 Sagami Chem Res INDOLYLPYRROLE DERIVATIVES AND CELL DEATH INHIBITORS
PL209780B1 (en) 2000-05-11 2011-10-31 Consejo Superior Investigacion Heterocyclic inhibitors of glycogen synthase kinase gsk−3
CA2452445C (en) 2000-06-29 2011-02-15 North Shore-Long Island Jewish Health System Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
US6962944B2 (en) 2001-07-31 2005-11-08 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US7074824B2 (en) 2001-07-31 2006-07-11 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US7060705B2 (en) 2001-11-07 2006-06-13 Merck & Co., Inc. Mitotic kinesin inhibitors
US6753428B2 (en) 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
WO2003066808A2 (en) 2002-01-23 2003-08-14 Texas Tech University Mammalian migration inducting gene and methods for detection and inhibition of migrating tumor cells
JP2005529076A (en) 2002-02-15 2005-09-29 サイトキネティクス・インコーポレーテッド Synthesis of quinazolinone
WO2003076442A1 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Purine derivatives as kinase inhibitors
US7214800B2 (en) 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
US7038048B2 (en) 2002-05-23 2006-05-02 Cytokinetics, Inc. 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use
EP1517904A4 (en) * 2002-05-23 2007-02-21 Merck & Co Inc Mitotic kinesin inhibitors
AU2003256805A1 (en) 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
EP1620573A4 (en) 2003-04-15 2006-12-20 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
ATE534649T1 (en) 2003-05-15 2011-12-15 Arqule Inc IMIDAZOTHIAZOLES AND IMIDAZOXAZOLE DERIVATIVES AS INHIBITORS OF P38
US7345046B2 (en) 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
WO2005001486A1 (en) 2003-06-06 2005-01-06 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
DE602004024536D1 (en) 2003-07-07 2010-01-21 Van Andel Res Inst INHIBITION OF TUMOR ANGIOGENESIS BY A COMBINATION OF THROMBOSPONDIN-1 AND INHIBITORS OF THE VASCULAR ENDOTHEL GROWTH FACTOR
US20050233960A1 (en) 2003-12-11 2005-10-20 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
JP2008517064A (en) 2004-10-19 2008-05-22 アークル インコーポレイテッド Synthesis of imidazooxazole and imidazothiazole inhibitors of P38 MAP kinase
RU2547148C2 (en) 2005-02-09 2015-04-10 Аркьюл, Инк. Compositions and methods of treating cancer
WO2006105511A1 (en) 2005-03-31 2006-10-05 The General Hospital Corporation Monitoring and modulating hgf/hgfr activity
US7501430B2 (en) * 2006-04-17 2009-03-10 Arqule, Inc. RAF inhibitors and their uses

Also Published As

Publication number Publication date
BRPI0813355A2 (en) 2014-12-30
US20090130097A1 (en) 2009-05-21
IL202740A0 (en) 2010-06-30
WO2009002808A3 (en) 2009-07-23
JP2010530885A (en) 2010-09-16
US8232285B2 (en) 2012-07-31
CA2704282A1 (en) 2008-12-31
CN101801937A (en) 2010-08-11
MX2009013815A (en) 2010-03-01
TW200918069A (en) 2009-05-01
WO2009002808A2 (en) 2008-12-31
AU2008268613A1 (en) 2008-12-31
EP2173724A2 (en) 2010-04-14
KR20100024494A (en) 2010-03-05
ZA201000183B (en) 2011-03-30

Similar Documents

Publication Publication Date Title
EP2173724B1 (en) Quinazolinone compounds and methods of use thereof
US20110217300A1 (en) Quinazolinone Compounds and Methods of Use Thereof
CA2592286C (en) Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
KR100847788B1 (en) Methods and Compositions Using Quinazolinone
CA2388646C (en) Methods and compositions utilizing quinazolinones
ES2369652T3 (en) C-MET MODULATORS AND METHODS OF USE.
ES2376552T3 (en) QUINAZOLINONE COMPOUNDS AS ANTICENT AGENTS? NCER.
AU2001259270A1 (en) Methods and compositions utilizing quinazolinones
JP2005529076A (en) Synthesis of quinazolinone
US7671200B2 (en) Quinazolinone KSP inhibitors
JP2006501201A (en) Compounds, compositions and methods
WO2009049305A2 (en) 5- (2-hydroxyphenyl) tetrazoles as hsp90 inhibitors against cancer
Yassen et al. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100115

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LIU, JIFENG

Inventor name: ALI, SYED, M.

Inventor name: PALMA, ROCIO

Inventor name: YOHANNES, DAN

Inventor name: ASHWELL, MARK, A.

Inventor name: YE, PING

Inventor name: GUAN, YOUSHENG

Inventor name: NG, SHI-CHUNG

17Q First examination report despatched

Effective date: 20101025

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

DAX Request for extension of the european patent (deleted)
GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 587220

Country of ref document: AT

Kind code of ref document: T

Effective date: 20121215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008020632

Country of ref document: DE

Effective date: 20130131

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 587220

Country of ref document: AT

Kind code of ref document: T

Effective date: 20121205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130316

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130305

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121205

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121205

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121205

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20121205

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121205

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121205

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121205

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130306

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121205

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121205

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121205

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130405

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121205

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130405

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121205

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121205

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121205

26N No opposition filed

Effective date: 20130906

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121205

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008020632

Country of ref document: DE

Effective date: 20130906

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121205

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130731

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130630

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130630

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130619

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121205

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130619

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20080619

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240509

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240509

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240509

Year of fee payment: 17